<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">93664</article-id>
<article-id pub-id-type="doi">10.7554/eLife.93664</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.93664.2</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.3</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
</subj-group>
</article-categories><title-group>
<article-title>Drug-induced changes in connectivity to midbrain dopamine cells revealed by rabies monosynaptic tracing</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bartas</surname>
<given-names>Katrina</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Derdeyn</surname>
<given-names>Pieter</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tian</surname>
<given-names>Guilian</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vasquez</surname>
<given-names>Jose J</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Azouz</surname>
<given-names>Ghalia</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yamamoto</surname>
<given-names>Cindy M</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hui</surname>
<given-names>May</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4934-1338</contrib-id>
<name>
<surname>Beier</surname>
<given-names>Kevin T</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
    <xref ref-type="aff" rid="a3">3</xref>
    <xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a5">5</xref>
<email>kbeier@uci.edu</email>
</contrib>
    <aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gyf1771</institution-id><institution>Program in Mathematical, Computational, and Systems Biology. University of California, Irvine</institution></institution-wrap>, <city>Irvine</city>, <country country="US">United States</country></aff>
    <aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gyf1771</institution-id><institution>Department of Physiology and Biophysics, University of California, Irvine</institution></institution-wrap>, <city>Irvine</city>, <country country="US">United States</country></aff>
    <aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gyf1771</institution-id><institution>Department of Neurobiology and Behavior, University of California, Irvine</institution></institution-wrap>, <city>Irvine</city>, <country country="US">United States</country></aff>
    <aff id="a4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gyf1771</institution-id><institution>Department of Biomedical Engineering, University of California, Irvine</institution></institution-wrap>, <city>Irvine</city>, <country country="US">United States</country></aff>
    <aff id="a5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gyf1771</institution-id><institution>Department of Pharmaceutical Sciences, University of California, Irvine</institution></institution-wrap>, <city>Irvine</city>, <country country="US">United States</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Uchida</surname>
<given-names>Naoshige</given-names>
</name>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5755-9409</contrib-id><role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Harvard University</institution>
</institution-wrap>
<city>Cambridge</city>
<country country="US">United States</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Wassum</surname>
<given-names>Kate M</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/046rm7j60</institution-id><institution>University of California, Los Angeles</institution>
</institution-wrap>
<city>Los Angeles</city>
<country country="US">United States</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="coi-statement"><p>Competing interests: No competing interests declared</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2024-04-08">
<day>08</day>
<month>04</month>
<year>2024</year>
</pub-date>
<pub-date date-type="update" iso-8601-date="2026-02-03">
<day>03</day>
<month>02</month>
<year>2026</year>
</pub-date>
<volume>13</volume>
<elocation-id>RP93664</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2024-01-26">
<day>26</day>
<month>01</month>
<year>2024</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2022-12-17">
<day>17</day>
<month>12</month>
<year>2022</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.12.16.520804"/>
</event>
<event>
<event-desc>Reviewed preprint v1</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2024-04-08">
<day>08</day>
<month>04</month>
<year>2024</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.93664.1"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.93664.1.sa3">eLife assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.93664.1.sa2">Reviewer #1 (Public Review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.93664.1.sa1">Reviewer #2 (Public Review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.93664.1.sa0">Reviewer #3 (Public Review):</self-uri>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2024, Bartas et al</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Bartas et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-93664-v2.pdf"/>
<abstract><p>Addictive drugs cause long-lasting changes in connectivity from inputs onto ventral tegmental area dopamine cells (VTA<sup>DA</sup>) that contribute to drug-induced behavioral adaptations. However, it is not known which inputs are altered. Here we used a rabies virus (RABV)-based mapping strategy to quantify RABV-labeled inputs to VTA cells after a single exposure to one of a variety of misused drugs – cocaine, amphetamine, methamphetamine, morphine, and nicotine – and compared the relative global input labeling across conditions. We observed that all tested addictive drugs elicited similar input changes onto VTA<sup>DA</sup> cells, in particular onto DA cells projecting to the lateral shell of the nucleus accumbens and amygdala. In addition, repeated administration of ketamine/xylazine to induce anesthesia induces a change in inputs to VTA<sup>DA</sup> cells that is similar to but different from those elicited by a single exposure to addictive drugs, suggesting that caution should be taken when using ketamine/xylazine-based anesthesia in rodents when assessing motivated behaviors. Furthermore, comparison of viral tracing data to an atlas of gene expression in the adult mouse brain showed that the basal expression patterns of several gene classes, especially calcium channels, were highly correlated with the extent of both addictive drug- or ketamine/xylazine-induced changes in RABV-labeled inputs to VTA<sup>DA</sup> cells. Reducing expression levels of the voltage-gated calcium channel <italic>Cacna1e</italic> in cells in the nucleus accumbens lateral shell reduced RABV-mediated input labeling of these cells into VTA<sup>DA</sup> cells. These results directly link genes controlling cellular excitability and the extent of input labeling by RABV.</p>
</abstract>
<funding-group>
<award-group id="par-1">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id>
<institution>HHS | National Institutes of Health (NIH)</institution>
</institution-wrap>
</funding-source>
<award-id>R00 DA041445</award-id>
<principal-award-recipient>
<name>
<surname>Beier</surname>
<given-names>Kevin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-2">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id>
<institution>HHS | National Institutes of Health (NIH)</institution>
</institution-wrap>
</funding-source>
<award-id>DP2 AG067666</award-id>
<principal-award-recipient>
<name>
<surname>Beier</surname>
<given-names>Kevin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-3">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id>
<institution>HHS | National Institutes of Health (NIH)</institution>
</institution-wrap>
</funding-source>
<award-id>R01 DA054374</award-id>
<principal-award-recipient>
<name>
<surname>Beier</surname>
<given-names>Kevin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-4">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id>
<institution>HHS | National Institutes of Health (NIH)</institution>
</institution-wrap>
</funding-source>
<award-id>R01 DA056599</award-id>
<principal-award-recipient>
<name>
<surname>Beier</surname>
<given-names>Kevin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-5">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id>
<institution>HHS | National Institutes of Health (NIH)</institution>
</institution-wrap>
</funding-source>
<award-id>R01 NS130044</award-id>
<principal-award-recipient>
<name>
<surname>Beier</surname>
<given-names>Kevin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-6">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/00pjdza24</institution-id>
<institution>Tobacco-Related Disease Research Program (TRDRP)</institution>
</institution-wrap>
</funding-source>
<award-id>T31KT1437</award-id>
<principal-award-recipient>
<name>
<surname>Beier</surname>
<given-names>Kevin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-7">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/00pjdza24</institution-id>
<institution>Tobacco-Related Disease Research Program (TRDRP)</institution>
</institution-wrap>
</funding-source>
<award-id>T31P1426</award-id>
<principal-award-recipient>
<name>
<surname>Beier</surname>
<given-names>Kevin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-8">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/04sedwh45</institution-id>
<institution>American Parkinson Disease Association (APDA)</institution>
</institution-wrap>
</funding-source>
<award-id>APDA-5589562</award-id>
<principal-award-recipient>
<name>
<surname>Beier</surname>
<given-names>Kevin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-9">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/0375f4d26</institution-id>
<institution>Alzheimer's Association (AA)</institution>
</institution-wrap>
</funding-source>
<award-id>AARG-NTF-20-685694</award-id>
<principal-award-recipient>
<name>
<surname>Beier</surname>
<given-names>Kevin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-10">
<funding-source>
<institution-wrap>
<institution>New Vision Research</institution>
</institution-wrap>
</funding-source>
<award-id>CCAD2020-002</award-id>
<principal-award-recipient>
<name>
<surname>Beier</surname>
<given-names>Kevin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-11">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/03cvfxv40</institution-id>
<institution>BrightFocus Foundation (BFF)</institution>
</institution-wrap>
</funding-source>
<award-id>A2022031S</award-id>
<principal-award-recipient>
<name>
<surname>Beier</surname>
<given-names>Kevin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-12">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/03a63f080</institution-id>
<institution>Brain and Behavior Research Foundation (BBRF)</institution>
</institution-wrap>
</funding-source>
<award-id>NARSAD 26845</award-id>
<principal-award-recipient>
<name>
<surname>Beier</surname>
<given-names>Kevin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-13">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id>
<institution>HHS | National Institutes of Health (NIH)</institution>
</institution-wrap>
</funding-source>
<award-id>T32 GM008620</award-id>
<principal-award-recipient>
<name>
<surname>Hui</surname>
<given-names>May</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-14">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id>
<institution>HHS | National Institutes of Health (NIH)</institution>
</institution-wrap>
</funding-source>
<award-id>F30 DA056215</award-id>
<principal-award-recipient>
<name>
<surname>Hui</surname>
<given-names>May</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-15">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id>
<institution>HHS | National Institutes of Health (NIH)</institution>
</institution-wrap>
</funding-source>
<award-id>T32 GM136624</award-id>
<principal-award-recipient>
<name>
<surname>Bartas</surname>
<given-names>Katrina</given-names>
</name>
</principal-award-recipient>
    <principal-award-recipient>
        <name>
            <surname>Derdeyn</surname>
            <given-names>Pieter</given-names>
        </name>
    </principal-award-recipient>
</award-group>
<award-group id="par-17">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/021nxhr62</institution-id>
<institution>National Science Foundation (NSF)</institution>
</institution-wrap>
</funding-source>
<award-id>GRFP DGE-1839285</award-id>
<principal-award-recipient>
<name>
<surname>Derdeyn</surname>
<given-names>Pieter</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>We revised the manuscript to address referee comments following submission to eLife.</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>The ventral tegmental area (VTA) contains dopamine cells (VTA<sup>DA</sup>) that play key roles in several behavioral processes, including reward, aversion, and motor control<sup><xref ref-type="bibr" rid="c1">1</xref>–<xref ref-type="bibr" rid="c3">3</xref></sup>. VTA<sup>DA</sup> cells are heterogeneous, with recent studies identifying subpopulations of VTA<sup>DA</sup> cells that differentially contribute to adaptive and pathological behaviors<sup><xref ref-type="bibr" rid="c4">4</xref>–<xref ref-type="bibr" rid="c7">7</xref></sup>. Numerous studies have mapped the input- output architecture of VTA cells generally, as well as subpopulations of constituent DAergic, GABAergic, and glutamatergic cells<sup><xref ref-type="bibr" rid="c7">7</xref>–<xref ref-type="bibr" rid="c12">12</xref></sup>. These studies have helped us to understand the biased input and discrete output logic of the VTA, as well as generate hypotheses regarding the function of circuits including the VTA.</p>
<p>In addition to normal adaptive behaviors, VTA<sup>DA</sup> cells critically contribute to a variety of behaviors related to substance use disorder (SUD), including reward, sensitization, and withdrawal elicited by addictive drugs<sup><xref ref-type="bibr" rid="c13">13</xref>–<xref ref-type="bibr" rid="c18">18</xref></sup>. For a variety of misused drugs, even a single exposure triggers long- lasting changes in synaptic plasticity onto VTA<sup>DA</sup> cells<sup><xref ref-type="bibr" rid="c19">19</xref>,<xref ref-type="bibr" rid="c20">20</xref></sup>. These changes include both a long- lasting enhancement of excitatory synaptic strength onto VTA<sup>DA</sup> cells<sup><xref ref-type="bibr" rid="c20">20</xref></sup>, and development of inhibitory synaptic plasticity<sup><xref ref-type="bibr" rid="c21">21</xref>,<xref ref-type="bibr" rid="c22">22</xref></sup>. These changes are essential for a variety of drug-induced behaviors, linking plasticity at VTA<sup>DA</sup> cells with downstream behavioral changes<sup><xref ref-type="bibr" rid="c22">22</xref>–<xref ref-type="bibr" rid="c24">24</xref></sup>. Furthermore, the changes in excitatory synaptic plasticity specifically occur onto some cell types and not others<sup><xref ref-type="bibr" rid="c5">5</xref></sup>, indicating that these adaptations are likely cell type- and pathway-specific. However, it remains unknown which sets of inputs are modified, and if these changes are consistent across misused drugs. Furthermore, synaptic plasticity is not the only type of long-lasting change that can be induced by addictive drugs. Unfortunately, even less is known about how other forms of experience-dependent changes, including elevations in input activity, may contribute to addiction- related behaviors.</p>
<p>We recently showed that a single dose of cocaine causes long-lasting changes in cellular activity in inputs to VTA<sup>DA</sup> cells<sup><xref ref-type="bibr" rid="c15">15</xref>,<xref ref-type="bibr" rid="c16">16</xref></sup>. These changes occur from the globus pallidus external segment (GPe) and bed nucleus of the stria terminalis (BNST) projections to the VTA that contribute to drug- induced reward and sensitization, or withdrawal anxiety, respectively<sup><xref ref-type="bibr" rid="c15">15</xref>,<xref ref-type="bibr" rid="c25">25</xref></sup>. Notably, while these studies focused on inputs from the GPe and BNST, the viral mapping results also demonstrated the existence of other input changes to the VTA that were not pursued in those studies. These unexplored connections may provide critical information about how drugs alter connectivity onto VTA<sup>DA</sup> cells, which in turn contributes to drug-induced behavioral changes<sup><xref ref-type="bibr" rid="c15">15</xref>,<xref ref-type="bibr" rid="c16">16</xref></sup>.</p>
<p>In this study, we explore the brain-wide changes in RABV-labeled inputs to VTA cells elicited by a variety of different drugs, including addictive drugs, an anesthetic mixture of ketamine/xylazine (K/X), and fluoxetine, a psychoactive but non-addictive control substance. Our study provides a first-of-its-kind exploration into how even a single drug exposure can change brain-wide connectivity patterns, in addition to highlighting some concerns about the potential effects of K/X anesthesia on motivated behavior.</p>
</sec>
<sec id="s2">
<title>Materials and methods</title>
<sec id="s2a">
<title>Experimental Procedures</title>
<sec id="s2a1">
<title>Animals</title>
<p>Mice were housed on a 12-hour light–dark cycle with food and water ad libitum. Males and females from a C57/BL6 background were used for all experiments in approximately equal proportions. Mice were approximately 3-4 months of age at the time of experiments. All surgeries were done under isoflurane or ketamine/xylazine anesthesia. All procedures complied with the animal care standards set forth by the National Institute of Health and were approved by the University of California, Irvine’s Institutional Animal Care and Use Committee (IACUC).</p>
</sec>
<sec id="s2a2">
<title>Stereotaxic surgery</title>
<p>Mice were anesthetized with 3-4% isoflurane and maintained during surgery at 1-1.5% isoflurane, or with a mixture of ketamine (100 mg/mL) and xylazine (5 mg/mL). Mice were secured in a stereotaxic apparatus (Stoelting). Under aseptic conditions, guide holes were drilled, and viruses were infused into the target sites using a glass capillary attached to a microinjection pump (WPI, UMP3T). 100 nL of AAVs or 500 nL of EnvA-pseudotyped RABV were infused at a rate of 1.6 nL/s. The glass capillary remained in place for 5 min following the infusion to allow for virus diffusion. After infusion, the surgical incision sites were closed with either sutures or Vetbond tissue adhesive (Patterson Veterinary). Vetameg (flunixin, Patterson veterinary) was administered for pain management and topical bacitracin was applied to prevent infection at the incision site.</p>
<p>For viral injections mapping experiments from a defined cell type, 100 nL of a 1:1 volume mixture of AAV<sub>5</sub>-CAG-FLEx<sup>loxP</sup>-TCB and AAV<sub>8</sub>-CAG-FLEx<sup>loxP</sup>-RABV-G was injected into the VTA of DAT- Cre<sup><xref ref-type="bibr" rid="c26">26</xref></sup>, GAD2-Cre<sup><xref ref-type="bibr" rid="c27">27</xref></sup>, or vGluT2-Cre mice<sup><xref ref-type="bibr" rid="c28">28</xref></sup>. Thirteen days later, animals were given a single injection of an addictive drug, fluoxetine, or saline. The following day, 500 nL of EnvA- pseudotyped RABV was injected into the VTA. Animals were sacrificed five days later. For cTRIO experiments shown in <xref rid="fig7" ref-type="fig">Figure 7</xref>, during the first surgery AAV<sub>5</sub>-CAG-FLEx<sup>FRT</sup>-TCB and AAV<sub>8</sub>-CAG- FLEx<sup>FRT</sup>-RABV-G were injected into the VTA, and CAV2-FLEx<sup>loxP</sup>-Flp was injected into an output site (NAcLat, Amygdala, NAcMed, mPFC) during the same surgery. All other procedures were the same as above. RABV-labeled cells throughout the brain were manually quantified, as done previously<sup><xref ref-type="bibr" rid="c7">7</xref>,<xref ref-type="bibr" rid="c10">10</xref>,<xref ref-type="bibr" rid="c15">15</xref></sup>.</p>
<p>The injection coordinates and volumes used were as follows:</p>
<p>VTA: 100 nL AAV and 500 nL RABV, AP –3.2, LM 0.4, DV –4.2</p>
<p>NAcMed: 250 nL, AP +1.78, L0.4, DV –4.1</p>
<p>NAcLat: 250 nL, AP +1.45, LM 1.75, DV –4.0</p>
<p>Amygdala: 500 nL, AP –1.43, LM 2.5, DV –4.5</p>
<p>mPFC: 1 μL into mPFC (two injections of 500 nL, one at AP +2.15, LM 0.27, DV –2.1 and another at AP +2.15, L0.27, DV –1.6</p>
<p>The titers of the viruses used, based on quantitative PCR analysis, were as follows: AAV<sub>5</sub>-CAG-FLEx<sup>loxP</sup>-TC, 2.4 x 10<sup>13</sup> genome copies (gc)/mL;</p>
<p>AAV<sub>8</sub>-CAG-FLEx<sup>loxP</sup>-G, 1.0 x 10<sup>12</sup> gc/mL;</p>
<p>AAV<sub>5</sub>-CAG-FLEx<sup>FRT</sup>-TC, 2.6 x 10<sup>12</sup> gc/mL;</p>
<p>AAV<sub>8</sub>-CAG-FLEx<sup>FRT</sup>-G, 1.3 x 10<sup>12</sup> gc/mL;</p>
<p>CAV-FLEx<sup>loxP</sup>-Flp, 5.0 x 10<sup>12</sup> gc/mL.</p>
<p>The titer of RABVΔG was estimated to be 5.0 x 10<sup>8</sup> colony forming units (cfu)/mL based on serial dilutions of the virus stock followed by infection of the 293-TVA800 cell line.</p>
<p>Drug administration: Cocaine was administered (intraperitoneal injections) at a dose of 15 mg/kg, morphine at 10 mg/kg, methamphetamine at 2 mg/kg, amphetamine at 10 mg/kg, nicotine at 0.5 mg/kg, and fluoxetine at 10 mg/kg.</p>
</sec>
<sec id="s2a3">
<title>Quantification of RABV data</title>
<p>RABV mapping data were analyzed as described previously<sup><xref ref-type="bibr" rid="c7">7</xref>,<xref ref-type="bibr" rid="c10">10</xref></sup>. All RABV mapping data included were previously published<sup><xref ref-type="bibr" rid="c7">7</xref>,<xref ref-type="bibr" rid="c10">10</xref>,<xref ref-type="bibr" rid="c15">15</xref></sup>, except for input tracing from mice treated with a single dose of methamphetamine. The SAD B19 vaccine stain was used for all experiments. A total of 118 samples were included in this study (Table 1). Exclusion criteria included mice in which fewer than 200 input cells were labeled, or in cases where injections were mistargeted (e.g., starter cells in the substantia nigra pars compacta). Experimenters were blinded to the experimental condition when data quantification was being performed. For starter cell center of mass calculations, we mapped the distribution of starter neurons, as defined by TVA-mCherry expression along the A-P axis, and in the sections at the center point along this axis, defined the center of labeling in along the M-L axis.</p>
</sec>
</sec>
<sec id="s2b">
<title>CRISPRi experiments</title>
<sec id="s2b1">
<title>Plasmid construction</title>
<p>The CRISPRi system was adapted from Kumar’s method<sup><xref ref-type="bibr" rid="c29">29</xref></sup>. pJEP317 pAAV-U6SaCas9gRNA(SapI)-EFS-GFP-KASH-pA was obtained from Addgene and was used as a template to clone pJEP317-pAAV-U6-Cacna1eAC-EFS-GFP-KASH-pA using the Q5 Site- directed mutagenesis kit (primers: 5’-<named-content content-type="sequence">acctccgtaaGTTTTAGTACTCTGGAAACAG</named-content>-3’ and 5’- <named-content content-type="sequence">atgaacccttGGTGTTTCGTCCTTTCCAC</named-content>-3’) to insert the gRNA sequence (<named-content content-type="sequence">AAGGGTTCATACCTCCGTAA</named-content>) for <italic>Cacna1e</italic>. The gRNA sequence was selected from the IDT Predesigned Alt-R™ CRISPR-Cas9 guide RNA resource (<ext-link ext-link-type="uri" xlink:href="https://www.idtdna.com/site/order/designtool/index/CRISPR_PREDESIGN">https://www.idtdna.com/site/order/designtool/index/CRISPR_PREDESIGN</ext-link>). The plasmid for CRISPRi (pJEP309-pAAV-EFS-dSaCas9-KRAB-Dio-pA), pAAV2-8, and pAAV2-5 were obtained from Addgene. pHelper plasmid was a gift from Matthew Banghart at the University of California, San Diego.</p>
</sec>
<sec id="s2b2">
<title>AAV production, purification, and titering</title>
<p>Generation of AAVs from plasmids and AAV Purification by Iodixanol Gradient Ultracentrifugation were carried out as described on Addgene’s website with minor modifications. Briefly, pHelper, pAAV2-5/pAAV2-8 and pJEP309/pJEP317- pAAV-U6-Cacna1eAC-EFS-GFP-KASH-pA plasmids were transfected into HEK293T cells using PEIMAX (Polysciences, cat# 24765-100). The molar ratio for pHelper:pAAV2-5:transfer plasmid was 1:1:1, and the ratio of total plasmids to PEIMAX was 1:3. 72 hrs post-transfection, cell lysate and medium precipitated with PEG were purified by iodixanol gradient. Purified AAVs were titered using primers against viral ITRs (5’-<named-content content-type="sequence">GGAACCCCTAGTGATGGAGTT</named-content>-3’ and 5’- <named-content content-type="sequence">CGGCCTCAGTGAGCGA</named-content>-3’).</p>
</sec>
<sec id="s2b3">
<title>Viral injection</title>
<p>Prior to surgery, DAT-Cre mice were anesthetized with isoflurane (4% induction, 1-1.5% maintenance) and secured on a stereotaxic frame for precise localization of injection sites. For assessment of <italic>in vivo</italic> genome editing, two conditions were generated. For the experimental condition, 600 nL of a 1:1:1 volume mix of AAV<sub>8</sub>-EFS-dSaCas9-KRAB-Dio, AAV<sub>9</sub>-CamKII-0.4- Cre-SV40 (Addgene, cat# 05558-AAV9) and AAV<sub>5</sub>-U6-Cacna1eAC-EFS-GFP-KASH was injected into the NAcLat. For a no gRNA control condition, 400 nL of a 1:1 volume mix of AAV<sub>8</sub>- EFS-dSaCas9-KRAB-Dio and AAV<sub>9</sub>-CamKII-0.4-Cre-SV40 was infused into the NAcLat.</p>
<p>For mapping inputs to VTA cells in mice with <italic>Cacna1e</italic> downregulation in NAcLat, during a single surgery, 300 nL of a of a 1:1 volume mix of AAV<sub>5</sub>-FLEx<sup>loxP</sup>-TC and AAV<sub>5</sub>-FLEx<sup>loxP</sup>-RABV-G was injected into the VTA bilaterally, 600 nL of a 1:1:1 volume mix of AAV<sub>8</sub>-EFS-dSaCas9-KRAB-Dio, AAV<sub>9</sub>-CamKII-0.4-Cre-SV40, and AAV<sub>5</sub>-U6-Cacna1eAC-EFS-GFP-KASH was injected into the left NAcLat, and 400 nL of a 1:1 volume mix of AAV<sub>8</sub>-EFS-dSaCas9-KRAB-Dio and AAV<sub>9</sub>-CamKII- 0.4-Cre-SV40 was injected into the right NAcLat. This study design enabled controls within the same mice to prevent systematic biases due to differences in treatment of the mice. After 14 days, RABVΔG was injected into the VTA. Mice were sacrificed five days later, and brains processed as described below.</p>
</sec>
<sec id="s2b4">
<title>Brain section preparation, imaging, and cell counting</title>
<p>Five days after RABV injection, mice underwent transcardial perfusion with 1x PBS followed by 4% formaldehyde in 1x PBS. Brains were extracted and post-fixed in 4% formaldehyde for 24 hours, and then dehydrated with 30% sucrose in 1x PBS. Brains were cut into 60 µm slices using a cryostat and mounted on Superfrost Plus<sup>TM</sup> microscope slides (Fisher, cat # 1255015). Once the brain sections were fully dried on the slide, they were rehydrated in 1xPBS containing DAPI at a dilution of 1:1000 (ThermoFisher, cat# D1306). After 10 minutes, the liquid was removed, and Fluoromount-G (SouthernBiotech, cat# 0100-01) was applied to the sections. Coverslips (Thermo Scientific, cat# 152460) were used to cover the brain sections on the slides. Images of the entire slides were captured using an Olympus IX83 microscope, and manual cell counting was performed on the acquired images.</p>
</sec>
<sec id="s2b5">
<title>Determination of CRISPRi-mediated knockdown efficiency</title>
<p>To determine the efficacy of CRISPRi knockdown of <italic>Cacna1e</italic> expression levels, 10 days following AAV injections into the NAcLat, NAcLat brain tissue was dissected out from the brains of injected mice, and tissue was pooled (5 mice for <italic>Cacna1e</italic> gRNA and 3 mice for no gRNA control). Total RNA was extracted with TRIzol, and 50 ng of total RNA was used for RT-qPCR using the Luna Universal One-Step RT-qPCR Kit (New England Biolabs, cat# E3005L) following the manufacturer’s instructions. Phosphoglycerate Kinase 1 (PGK1) was used as the housekeeping gene for normalization of <italic>Cacna1e</italic> mRNA levels.</p>
</sec>
</sec>
<sec id="s2c">
<title>Dimensionality reduction of RABV input data</title>
<p>For RABV input mapping experiments, quantified inputs cells were binned into 22 regions: Cortex (anterior cortex), NAcMed, NAcLat, NAcCore, DStr, VP, PO, Septum, BNST, EAM, EP, GPe, PVH, LHb, MHb, CeA, LH, ZI, DR, LDT, PBN, and DCN. Altogether, this dataset consists of the input cell counts for these 22 regions across 118 mouse brains, with n=4 or 5 for each condition.</p>
<p>RABV input tracing data were reported as the percentage of total quantified labeled RABV inputs, as reported previously<sup><xref ref-type="bibr" rid="c7">7</xref>,<xref ref-type="bibr" rid="c10">10</xref></sup>. These data were further scaled using Z-score normalization. Principal Component Analysis (PCA) was then implemented on these normalized data using the scikit learn library in Python with default parameters<sup><xref ref-type="bibr" rid="c30">30</xref></sup>. Weights for PCA models were visualized as heatmaps, reflecting the contribution of each feature to each principal component. To test for differences between groups visualized in PC space, we assessed the value for each brain for each PC and if comparing 2 conditions, used an unpaired t-test, and if &gt;2 conditions, a one-way ANOVA and if p &lt; 0.05, followed by pairwise t-tests with multiple comparisons corrections (Dunnett or Tukey, as appropriate). Input values were the first 3 principal components, and significant differences between conditions for each principal component (drugs versus controls, for example) were denoted as having a p-value of less than 0.05. Results are reported where relevant in the text or in Table S2.</p>
<p>Uniform Manifold Approximation and Projection (UMAP), implemented using the UMAP library in Python, was used to generate alternative visualizations of the RABV input data<sup><xref ref-type="bibr" rid="c31">31</xref></sup>. To choose and standardize our UMAP parameters across analyses, we investigated which methods placed mouse brains of the same type and treatment close together most consistently. For the distance metric parameter, the metrics we found to perform best were Euclidean and cosine, but we chose to use the Euclidean metric for consistency with previous analyses<sup><xref ref-type="bibr" rid="c32">32</xref></sup>. For the number of neighbors parameter, we chose a large number, ⅓ the size of each of our datasets, for a more global view of the data. Other parameters were kept at the default values. To account for the stochasticity of individual embeddings, we applied UMAP 20 times to each data set and found the results to be very similar, as found in previous analyses<sup><xref ref-type="bibr" rid="c32">32</xref></sup>. The results were then presented as correlograms. Clustered heatmaps and plots of these data were made using a combination of the Python packages seaborn<sup><xref ref-type="bibr" rid="c33">33</xref></sup> and matplotlib<sup><xref ref-type="bibr" rid="c34">34</xref></sup>. The seaborn clustermap function was implemented with default values, including Euclidean distance as the distance metric.</p>
<p>Each PCA and UMAP representation of data show each animal as a point, and each point is colored by the relevant condition, either genotype or drug administered. To better visualize the distribution of a given condition in PCA and UMAP space, we overlaid the points with ellipsoids. Ellipsoids were centered at the average coordinate of a condition and stretched one standard deviation along the primary and secondary axes.</p>
</sec>
<sec id="s2d">
<title>Brain Region Selection in the Allen Mouse Brain Atlas</title>
<p>To compare our data with connectivity data from the Allen Institute, we converted our 22 brain regions into regions or groups of regions defined by the Allen Atlas. This was necessary as our region annotations defined while doing cell counts of the RABV data were at times different from the Allen Mouse Brain Atlas-defined regions. 22 brain regions were used for RABV analyses, but these were reduced to 20 brain regions (NAcMed, NAcLat, and NAcCore were merged into the NAc) for comparison with Allen Atlas data. In several cases, multiple Allen-defined regions were used to constitute a single region that we defined, as in the case of the cortex. A summary of these conversions is as follows:</p>
<table-wrap id="utbl1" orientation="portrait" position="float">
<graphic xlink:href="520804v3_utbl1.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="520804v3_utbl1a.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
    <p>It is important to note that these conversions are approximate, and brain-region specific results should be interpreted with caution, as there are known differences between atlases used in this work<sup><xref ref-type="bibr" rid="c35">35</xref></sup>. Representative images with boundaries showing every region on at least one section is shown in <xref ref-type="fig" rid="figs1">Figure S1</xref>.</p>
</sec>
<sec id="s2e">
<title>Allen Mouse Brain Connectivity Atlas projection portrait construction</title>
    <p>Projection portraits of the VTA were made using data from the Allen Mouse Brain Connectivity Atlas<sup><xref ref-type="bibr" rid="c36">36</xref></sup>, as described previously<sup><xref ref-type="bibr" rid="c32">32</xref></sup>. Briefly, data from 20 input brain regions, as defined in the above table, were downloaded and used for analyses. Cre-based and non-Cre-based experiments representative of each brain region were chosen for visualization. Labeled cell bodies at the site of injection often spread into adjacent brain regions or only covered a part of a region. Several experiments were chosen to account for this variation and give a better estimate for each region’s projections. Experiment IDs are recorded in Table S1 and in our previous work<sup><xref ref-type="bibr" rid="c32">32</xref></sup>. Connectivity of brain regions of interest to the VTA was visualized by showing a representative slice of the VTA and coloring the image based on high or low connectivity according to averaged AAV tracing data. AAV tracing data were averaged across experiments and across brain regions that grouped together according to weights assigned by PCA, as shown in <xref rid="fig2" ref-type="fig">Figures 2</xref>, <xref ref-type="fig" rid="fig6">6</xref>, and <xref ref-type="fig" rid="fig7">7</xref>.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1:</label>
<caption>
<title>PCA-based dimensionality reduction of RABV input tracing to 3 different VTA cell types.</title>
<p>(A) Schematic and timeline of viral injections into mice. (B) Representative images of the BNST, GPe, and DCN of DAT-Cre, GAD2-Cre, and vGlut2-Cre mice. Green indicates RABV-labeled cells. Scale, 200 μm. (C) Bar plot showing percent of RABV-labeled cells in each input region for DAT-Cre, GAD2-Cre, and vGlut2-Cre mice. (D) PCA of input labeling from brains from DAT-Cre, GAD2-Cre, and vGlut2-Cre mice. For this and other figures, ellipsoids were centered at the average coordinate of a condition and stretched one standard deviation along the primary and secondary axes. (E) Box plot comparisons of PC1. One-way ANOVA p = 0.010, pairwise t-tests DAT-Cre vs. GAD2-Cre multiple comparisons adjusted p = 0.0087, DAT-Cre vs. vGluT2-Cre p = 0.46, GAD2- Cre vs. vGluT2-Cre p = 0.19. n=8 for DAT-Cre, n = 13 for GAD2-Cre, and n = 7 for vGluT2-Cre. (F) Box plot comparisons of PC2. One-way ANOVA p = 0.016, pairwise t-tests DAT-Cre vs. GAD2-Cre multiple comparisons adjusted p = 0.65, DAT-Cre vs. vGluT2-Cre p = 0.016, GAD2- Cre vs. vGluT2-Cre p = 0.051. (G) Heatmap of the contributions of each brain region, or feature, in the data to PCs 1 through 3. For this and all figures, error bars = ± 1 SEM, * p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001, **** p &lt; 0.0001.</p>
</caption>
<graphic xlink:href="520804v3_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2:</label>
<caption>
<title>Projection portraits and UMAP of RABV inputs to VTA cells.</title>
<p>(A) Schematic of how projection portraits are constructed. A representative slice of the VTA is considered for experiments from the Allen Mouse Brain Connectivity Atlas with injections into relevant brain regions that provide input to the VTA. Projection density values in this slice are averaged and visualized to obtain the projection portrait in the VTA for that group of regions. (B) Projection portrait of the VTA based on inputs from regions with a high positive contribution to PC1: BNST, EP, GPe, CeA, and ZI. (C) Projection portrait of the VTA based on inputs from regions with a large negative contribution to PC1: anterior cortex, NAcMed, VP, PO, septum, LHb, MHb, and LH. (D) Projection portrait of the VTA based on inputs from regions with a high positive contribution to PC2: LHb, MHb, EP, ZI, DCN, and anterior cortex. (E) Projection portrait of the VTA based on inputs from regions with a large negative contribution to PC2: NAcMed, NAcLat, NAcCore, DStr, and GPe. (F) UMAP embedding of input labeling of brains from DAT-Cre, GAD2-Cre, and vGlut2-Cre mice. (G) Correlogram generated using the average Euclidean distance of data points from each other from 20 UMAP embeddings.</p>
</caption>
<graphic xlink:href="520804v3_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3:</label>
<caption>
<title>PCA can deconvolve drug-induced effects from experimental variation.</title>
<p>(A) Bar graph representation of inputs from DAT-Cre mice anesthetized with isoflurane and treated with a single injection of saline or fluoxetine. n = 4 for saline, n = 5 for fluoxetine. Two-way ANOVA interaction term p = 0.9365. (B) PCA plot showing PC1 and PC2 of brains from saline or fluoxetine-treated mice. (C) PCA plot showing PC2 and PC3 of brains from saline or fluoxetine-treated mice. (D) Box plot of PC1, p = 0.75. n = 4 for saline, n = 5 for fluoxetine. (E) Box plot of PC2, p = 0.78. (F) Box plot of PC3, p = 0.81. (G) Bar graph representation of inputs from DAT-Cre mice anesthetized with isoflurane and treated with a single injection of saline or fluoxetine (controls), or one of the addictive drugs cocaine, methamphetamine, amphetamine, nicotine, or morphine. n = 9 for control, n = 24 for combined addictive drugs. Two-way ANOVA, interaction term p = 0.0001; unpaired t-tests with Sidak corrections for multiple comparisons DStr p = 0.0051, GPe p = 0.0036. (H) PCA plot showing PC1 and PC2 of brains from control or drug-treated mice. (I) PCA plot showing PC2 and PC3 of brains from control or drug-treated mice. (J) Box plot of PC1, p = 0.78. n = 9 for control, n = 24 for drugs. (K) Box plot of PC2, p = 0.0009. (L) Box plot of PC3, p = 0.024. (M) Heatmap of the contributions of each brain region to PC1 through PC3 for data shown in panels H-I.</p>
</caption>
<graphic xlink:href="520804v3_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4:</label>
<caption>
<title>Differences in starter cell location do not explain differences in RABV input labeling patterns between addictive drug and control groups.</title>
<p>(A) Distribution of the starter cell center of mass along the medial-lateral axis for each experimental condition. Saline n = 4, fluoxetine n = 5, cocaine n = 5, methamphetamine n = 4, amphetamine n = 5, nicotine n = 5, morphine n = 5. (B) PC1 vs. PC2 for control vs. drug conditions as shown in <xref rid="fig3" ref-type="fig">Figure 3H</xref>, with each point colored according to the medial-lateral coordinate of the center of mass of starter cells for each brain. (C) PC2 vs. PC3 for control vs. drug conditions as shown in <xref rid="fig3" ref-type="fig">Figure 3I</xref>, with each point colored according to the medial-lateral coordinate of the center of mass of starter cells for each brain. (D) Linear regression between the x-coordinate of the center of mass of starter cells for each brain vs. PC1. r<sup>2</sup> = 0.770, p = 1.62e-7, (E) Linear regression between the x-coordinate of the center of mass of starter cells for each brain vs. PC2. r<sup>2</sup> = 0.308, p = 0.082. (F) Linear regression between the x-coordinate of the center of mass of starter cells for each brain vs. PC3, r<sup>2</sup> = 0.085, p = 0.638.</p>
</caption>
<graphic xlink:href="520804v3_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5:</label>
<caption>
<title>Dimensionality reduction analysis of brains from animals treated with a single drug exposure.</title>
<p>(A) PCA plot showing PC1 and PC2 of brains from DAT-Cre and GAD2-Cre mice. DAT-Cre mice were anesthetized with K/X and treated with saline or anesthetized with isoflurane and treated with saline or one of the drugs cocaine, methamphetamine, amphetamine, nicotine, morphine, or fluoxetine. GAD2-Cre mice were anesthetized with isoflurane and treated with saline or cocaine. (B) Box plot of PC1, One-way ANOVA p &lt; 0.0001, pairwise t-tests DAT-Cre saline vs. DAT-Cre fluoxetine multiple comparisons adjusted p = 0.99, DAT-Cre saline vs. DAT-Cre K/X p = 1.0, DAT- Cre saline vs. DAT-Cre drugs p = 0.23, DAT-Cre saline vs. GAD2-Cre p &lt; 0.0001, DAT-Cre fluoxetine vs. DAT-Cre K/X p = 1.0, DAT-Cre fluoxetine vs. DAT-Cre drugs p = 0.46, DAT-Cre fluoxetine vs. GAD2-Cre p &lt; 0.0001, DAT-Cre K/X vs. DAT-Cre drugs p = 0.31, DAT-Cre K/X vs. GAD2-Cre p &lt; 0.0001, DAT-Cre drugs vs. GAD2-Cre p &lt; 0.0001. n = 4 for DAT-Cre saline and DAT-Cre K/X, n = 5 for DAT-Cre fluoxetine, n = 24 for DAT-Cre drugs, n = 17 for GAD2-Cre. (C) Heatmap of the contributions of each brain region to PC1 through PC3 for data shown in panel A. (D) Representative images of brain slices from DAT-Cre mice showing, from left to right, the NAc, BNST, GPe, and PBN. Scale, 500 μm. (E) Bar plot showing percentage of RABV-labeled cells in each input region for the DAT-Cre mice shown in panel A. (F) PCA plot showing PC1 and PC2 of brains from DAT-Cre mice anesthetized with isoflurane and treated with cocaine, methamphetamine, amphetamine, nicotine, morphine, fluoxetine, or saline, or anesthetized with K/X and treated with saline. (G) PC2 and PC3 of the same group of brains as shown in panel F. (H) Box plot of PC1, One-way ANOVA p = 0.81. (I) Box plot of PC2, One-way ANOVA p = 0.0093, pairwise t-tests DAT-Cre saline vs. DAT-Cre fluoxetine multiple comparisons adjusted p = 0.94, DAT-Cre saline vs. DAT-Cre K/X p = 0.87, DAT-Cre saline vs. DAT-Cre drugs p = 0.034, DAT-Cre fluoxetine vs. DAT-Cre K/X p = 0.99, DAT- Cre fluoxetine vs. DAT-Cre drugs p = 0.10, DAT-Cre K/X vs. DAT-Cre drugs p = 0.27. (J) Box plot of PC3, One-way ANOVA p = 0.086. (K) Heatmap of the contributions of each brain region to PC1 through PC3 for data shown in panels F and G.</p>
</caption>
<graphic xlink:href="520804v3_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Data for projection portraits and for subsequent network construction was accessed using the python Allen SDK package, developed and maintained by the Allen Institute for Brain Science.</p>
</sec>
<sec id="s2f">
<title>Gene Expression Data Access and Processing</title>
<p>Gene expression data was downloaded from the Allen Institute’s Anatomic Gene Expression Atlas (AGEA)<sup><xref ref-type="bibr" rid="c37">37</xref></sup>, an <italic>in situ</italic> hybridization dataset which has annotated expression of 19,932 genes to every brain region defined in the Allen Mouse Brain Atlas. We used code written by Eli Cornblath (<ext-link ext-link-type="uri" xlink:href="https://github.com/ejcorn/mouse_abi_tool">https://github.com/ejcorn/mouse_abi_tool</ext-link>) to access and download gene expression data for our regions of interest, as done in a previous study<sup><xref ref-type="bibr" rid="c38">38</xref></sup>. To ensure only high-quality data were included in our analyses, we filtered experiments based on metrics used in previous analyses of this dataset<sup><xref ref-type="bibr" rid="c39">39</xref></sup>. We retained genes for which there were data from coronal sections, or where the Pearson correlation coefficient across experiments was over 0.5 for a particular gene in our regions of interest. This filtering left us with 4,283 unique genes for the 36 Allen-defined brain regions to be aggregated to compare with our 22 quantified input sites from the RABV mapping data. We averaged data among brain regions that were defined differently in the atlas versus our RABV quantifications, which resulted in a total of 20 brain regions for comparative analyses, as detailed above. Data were normalized using a scaled sigmoid function, a method that is robust to outliers and was used in previous analyses of these data<sup><xref ref-type="bibr" rid="c40">40</xref></sup>.</p>
</sec>
<sec id="s2g">
<title>Gene expression data analysis and comparison to RABV data</title>
    <p>To investigate how basal gene expression might be correlated to connectivity changes after drug exposure, we used processed data from the AGEA. For each experimental condition, the RABV data for the drug-treated animals were compared to those of the saline-treated controls. To quantify this comparison, we computed a ratio, as used in <xref rid="fig9" ref-type="fig">Figures 9</xref> and <xref ref-type="fig" rid="figs10">S10</xref>-<xref ref-type="fig" rid="figs12">S12</xref>, by dividing the average RABV counts in each brain region for the experimental condition by the average RABV counts in each brain region for the saline condition. This resulted in a vector of 22 ratios for each experimental condition, one ratio for each brain region. We also computed a difference, as used in <xref rid="fig8" ref-type="fig">Figures 8</xref> and <xref ref-type="fig" rid="figs7">S7</xref>-<xref ref-type="fig" rid="figs9">S9</xref>, by subtracting the average RABV counts in each brain region for the experimental condition by the average RABV counts in each brain region for the saline control condition. This resulted in a vector of 22 differences for each drug comparison, one difference for each brain region.</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6:</label>
<caption>
<title>Projection portraits and UMAP plot of VTA<sup>DA</sup> cells following a single drug exposure.</title>
<p>(A) Projection portrait of the VTA based on inputs from regions with a large negative contribution to PC1, based on data from <xref rid="fig5" ref-type="fig">Figure 5K</xref>: NAcCore, NAcLat, DStr, GPe. (B) Projection portrait based on inputs from regions with a high positive contribution to PC1, based on data from <xref rid="fig5" ref-type="fig">Figure 5K</xref>: LHb, DR, VP, PO, EAM, LH. (C) Projection portrait based on inputs from regions with a high positive contribution to PC2, based on data from <xref rid="fig5" ref-type="fig">Figure 5K</xref>: EAM, PBN, DR, EP, LH, GPe, ZI. (D) Projection portrait based on inputs from regions with a large negative contribution to PC2, based on data from <xref rid="fig5" ref-type="fig">Figure 5K</xref>: NAcMed, NAcCore, DStr, Septum, MHb. (E) UMAP embedding of data from the brains of DAT-Cre mice shown in <xref rid="fig5" ref-type="fig">Figure 5E</xref>. (F) Correlogram showing average Euclidean distance of data points over 20 UMAP embeddings of the data presented in panel E.</p>
</caption>
<graphic xlink:href="520804v3_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="fig7" position="float" orientation="portrait" fig-type="figure">
<label>Figure 7:</label>
<caption>
<title>Dimensionality reduction analysis of brains from animals anesthetized with isoflurane and treated with either cocaine or saline, or anesthetized with ketamine/xylazine and treated with saline.</title>
<p>(A) PCA plot of input data from VTA<sup>DA</sup> cells from mice anesthetized either with isoflurane or K/X and given saline. Box plot comparisons of PC1 and PC2 are shown to the right. PC1, p = 0.086, PC2, p = 0.037, unpaired t-tests. n = 4 for both. (B) Bar plot showing percentage of RABV-labeled cells in each input region from mice anesthetized either with isoflurane or K/X and given saline. (C) Heatmap of the contributions from each brain region to PC1 to PC3 for data shown in panel A. (D) Projection portrait of regions with high PC1 contributions in all VTA<sup>DA</sup> cells: VP, PO, EAM, PVH, LH, PBN. (E) Projection portrait of regions with high PC2 contributions in VTA<sup>DA</sup> cells: NAcLat, DStr, GPe, PVH. (F) UMAP plot of input data from VTA<sup>DA</sup> cells from mice anesthetized either with isoflurane or K/X and given saline. (G) PCA plot of RABV input mapping experiments to VTA<sup>DA</sup>→NAcLat cells in mice anesthetized with isoflurane and given saline or cocaine, or anesthetized with K/X and given saline. Box plot comparisons of PC1 and PC2 are shown to the right. PC1, One-way ANOVA p = 0.0003, pairwise t-tests saline vs. cocaine multiple comparisons adjusted p = 0.011, saline vs. K/X p = 0.071, K/X vs. cocaine p = 0.0002. PC2, One-way ANOVA p = 0.16. n=4 for saline and K/X, n = 5 for cocaine. (H) Bar plot showing percent of RABV-labeled cells in each input region for cTRIO experiments from VTA<sup>DA</sup>→NAcLat cells. (I) Heatmap of the contributions from each brain region to PC1 to PC3 for data shown in panel G. (J) Projection portrait of regions with low PC1 contributions in VTA<sup>DA</sup>→NAcLat cells: cortex, NAcMed, NAcLat, NAcCore, septum, PVH, MHb. (K) Projection portrait of regions with high PC2 contributions in VTA<sup>DA</sup>→NAcLat cells: VP, PO, EAM, LHb, LH. (L) UMAP plot of input mapping experiments to VTA<sup>DA</sup>→NAcLat cells. (M) PCA plot of input mapping experiments to VTA<sup>DA</sup>→Amygdala cells. Box plot comparisons of PC1 and PC2 are shown to the right. PC1, One-way ANOVA p = 0.48. PC2, One-way ANOVA p = 0.30. n=4 for saline, n = 5 for K/X and cocaine. (N) Bar plot showing percent of RABV-labeled cells in each input region for cTRIO experiments from VTA<sup>DA</sup>→Amygdala cells. (O) Heatmap of the contributions of each brain region to PC1 to PC3 for data shown in panel M. (P) UMAP plot of input mapping experiments to VTA<sup>DA</sup>→Amygdala cells.</p>
</caption>
<graphic xlink:href="520804v3_fig7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="fig8" position="float" orientation="portrait" fig-type="figure">
<label>Figure 8:</label>
<caption>
<title>Gene ontology (GO) analysis of top 50 genes within the Allen Gene Expression Atlas correlated with differences in RABV input labeling obtained from experimental vs. control mice.</title>
<p>(A-B) GO from an average of the addictive drug conditions vs. saline-treated controls, all anesthetized using isoflurane. (C-D) GO from K/X-anesthetized vs. isoflurane-anesthetized saline-treated mice. Panels A and C show molecular function-related gene classes whose expression was positively correlated with RABV labeling differences, and panels B and D show GO analyses that reflect biological process-related gene classes whose expression was negatively correlated with RABV labeling differences.</p>
</caption>
<graphic xlink:href="520804v3_fig8.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="fig9" position="float" orientation="portrait" fig-type="figure">
<label>Figure 9:</label>
<caption><title>Relationship between RABV labeling ratio in addictive drug/saline-treated groups and mean basal gene expression of gene subgroups, subtypes of ion channels, and neurotransmitter receptors.</title>
<p>Linear regressions are shown for all five examined drugs against different gene classes expressed by brain region within the Allen Gene Expression Atlas, including (A) ion channel-related genes, (B) neurotransmitter-related genes, (C) synapse-related genes, (D) Ca<sup>2+</sup> channels, (E) Cl<sup>-</sup> channels, (F) K<sup>+</sup> channels, (G) Na<sup>+</sup> channels, (H) glutamate receptors, (I) acetylcholine receptors, (J) GABA receptors, (K) glycine receptors.</p></caption>
<graphic xlink:href="520804v3_fig9.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>We calculated the correlation of the condition-control differences with gene expression data for each region. The Spearman correlation coefficient between the gene expression across regions and our RABV differences was used because the correlative relationship between these values cannot be assumed to be linear. A similar method was used in previous analyses<sup><xref ref-type="bibr" rid="c39">39</xref></sup>. A high positive correlation between a gene and an experimental condition ratio was interpreted as a greater likelihood of a brain region to exhibit RABV labeling changes after drug exposure if this gene is highly expressed before drug exposure. A negative correlation between a gene and an experimental condition ratio was taken to mean this region would be more likely to exhibit RABV labeling changes after drug exposure if the gene expression level is low.</p>
    <p>We performed GO analysis on the top 50 most highly correlated genes and on the top 50 most negatively correlated genes. GO analysis was performed using the EnrichR package<sup><xref ref-type="bibr" rid="c41">41</xref></sup>. Lists of genes with highly positive or negative correlations to our condition differences were compared to GO annotations using the coding language R. The 2021 version of two databases were queried: GO Biological Process and GO Molecular Function. GO enrichment analysis results were visualized in dot plots using the package ggplot2, as shown in <xref rid="fig8" ref-type="fig">Figures 8</xref> and <xref ref-type="fig" rid="figs7">S7</xref>-<xref ref-type="fig" rid="figs9">S9</xref>. The ‘overlap’ term on the x-axis of these plots means the number of genes in the correlated gene lists that were also within the list of genes for the corresponding GO term.</p>
    <p>We next compared the drug/isoflurane ratios for a group of addictive drugs to gene expression of subsets of genes of interest (<xref rid="fig9" ref-type="fig">Figure 9</xref>, <xref ref-type="fig" rid="figs10">S10</xref>). Similar analyses were done for ketamine/xylazine and fluoxetine (<xref ref-type="fig" rid="figs11">Figure S11</xref>, <xref ref-type="fig" rid="figs12">S12</xref>). The subgroups of genes used were synapse-related genes<sup><xref ref-type="bibr" rid="c42">42</xref></sup>, ion-channel related gene<sup><xref ref-type="bibr" rid="c43">43</xref></sup>, neurotransmitter receptor-related genes<sup><xref ref-type="bibr" rid="c44">44</xref></sup>, differentially expressed genes related to substance dependence GWAS<sup><xref ref-type="bibr" rid="c45">45</xref></sup>, and exo- and endocytosis-related genes<sup><xref ref-type="bibr" rid="c46">46</xref></sup>. Other subsets of genes of interest were defined using the Guide to Pharmacology database<sup><xref ref-type="bibr" rid="c47">47</xref></sup>. Correlation coefficients (Spearman’s ρ) and p-values are reported in the figures.</p>
</sec>
</sec>
<sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>Dimensionality reduction methods identify differences in inputs of VTA cell populations</title>
<p>We and others previously showed that DAergic, GABAergic, and glutamatergic cells in the VTA receive inputs from similar brain regions, with some quantitative differences that varied depending on the study<sup><xref ref-type="bibr" rid="c10">10</xref>,<xref ref-type="bibr" rid="c12">12</xref></sup>. In our work we also showed that connectivity differences in the VTA are largely a consequence of spatial organization of cells within the VTA<sup><xref ref-type="bibr" rid="c7">7</xref>,<xref ref-type="bibr" rid="c10">10</xref>,<xref ref-type="bibr" rid="c32">32</xref></sup>. The fact that the distributions of these three VTA cell populations are largely spatially overlapping may explain why the global inputs to each population are similar. However, one limitation in interpreting these studies is that they focused on individual comparisons of input counts on a per region basis. While this is a common approach in analyzing viral tracing data, and useful for both hypothesis generation and testing, it fails to account for the higher-level organization of input patterns. Our goal here is to go beyond considering single brain regions and better understand the holistic connectivity patterns of different cell populations or drug treatment conditions.</p>
<p>Our first goal was to explore the potential differences in input patterns generated using RABV tracing to each of the DAergic, GABAergic, and glutamatergic neuron populations in the VTA using principal component analysis, PCA. A schematic of the experiment is shown in <xref rid="fig1" ref-type="fig">Figure 1A</xref>, with representative images of brain regions of interest in <xref rid="fig1" ref-type="fig">Figure 1B</xref>. A standard representation of these data, a bar plot, is shown in <xref rid="fig1" ref-type="fig">Figure 1C</xref>. PCA embedding resulted in the three cell populations clustering into largely distinct groups (<xref rid="fig1" ref-type="fig">Figure 1D</xref>). We considered the first two principal components (PCs), which explain the most variance in the data. In PC space, DAT-Cre brains were characterized by low PC1 and low PC2 values, GAD2-Cre brains by high PC1 values, and vGluT2-Cre brains by high PC2 values. The differences we noted were statistically significant: PC1 values of GAD2-Cre compared to DAT-Cre brains were significantly different (One-way ANOVA p = 0.010, DAT-Cre vs. GAD2-Cre multiple comparisons adjusted p = 0.0087; <xref rid="fig1" ref-type="fig">Figure 1E</xref>) and PC2 values of DAT-Cre compared to vGluT2-Cre brains were significantly different (One-way ANOVA p = 0.016, DAT-Cre vs. vGluT2-Cre multiple comparisons adjusted p = 0.016; <xref rid="fig1" ref-type="fig">Figure 1F</xref>). An advantage of PCA over other dimensionality reduction approaches is that, because it is a linear approach, the weights of each feature’s contribution to each PC can be clearly interpreted. In this case, we can infer which brain regions contribute most to the positive and negative dimensions of each PC. For example, in our data, DAT-Cre and GAD2-Cre brains were separated along PC1. Brain regions that contributed to the positive dimension of PC1 were the BNST, entopeduncular nucleus (EP), GPe, central amygdala (CeA), and zona incerta (ZI) (<xref rid="fig1" ref-type="fig">Figure 1G</xref>). These inputs were enriched onto GABAergic cells relative to DA cells (<xref rid="fig1" ref-type="fig">Figure 1C</xref>). To identify where in the VTA these input populations projected, we assembled projection portraits of these inputs to the VTA as we did previously<sup><xref ref-type="bibr" rid="c32">32</xref></sup>. This approach uses axonal projection data available from the Allen Mouse Brain Connectivity Atlas to generate spatial heatmaps that show “hotspots” of innervation in the midbrain<sup><xref ref-type="bibr" rid="c36">36</xref></sup>. We first selected experiments where GFP was expressed in the input regions of interest. Pixel values representing projection density were pulled from a representative coronal slice containing the VTA for each region. For a given set of inputs of interest, we averaged together their projections to the VTA to see if the group had any common spatial trends (<xref rid="fig2" ref-type="fig">Figure 2A</xref>). The projection portrait of the positive PC1 inputs indicated that they preferentially project dorsally and laterally to areas surrounding the VTA (<xref rid="fig2" ref-type="fig">Figure 2B</xref>). In contrast, the regions that contributed most strongly to the negative dimension of PC1 were the anterior cortex, nucleus accumbens medial shell (NAcMed), ventral pallidum (VP), preoptic area (PO), septum, lateral habenula (LHb), medial habenula (MHb), and lateral hypothalamus (LH). These inputs were more highly labeled in DAT-Cre mice. The projection portrait of these inputs highlights the whole VTA and not surrounding regions (<xref rid="fig2" ref-type="fig">Figure 2C</xref>). While the distribution of starter cells in the VTA in DAT-Cre and GAD2-Cre mice is spatially overlapping<sup><xref ref-type="bibr" rid="c7">7</xref></sup>, this analysis indicates that inputs with biases onto DA cells target the VTA itself while those biased onto GABAergic cells preferentially target areas dorsal and lateral to the VTA.</p>
<p>While DAT-Cre and GAD2-Cre conditions were separated along PC1, DAT-Cre and vGluT2-Cre conditions were separated along PC2. Regions that contributed to the positive dimension of PC2 included the LHb, MHb, EP, ZI, and deep cerebellar nuclei (DCN) as well as the cortex, while those contributing to the negative dimension included the NAcMed, nucleus accumbens lateral shell (NAcLat), nucleus accumbens core (NAcCore), dorsal striatum (DStr), and GPe (<xref rid="fig2" ref-type="fig">Figure 2D- E</xref>). The MHb and LHb both project medially in the VTA, whereas the NAcMed, NAcLat, NAcCore, DStr, and GPe all project laterally<sup><xref ref-type="bibr" rid="c32">32</xref></sup>. The projection portrait corresponding to the positive dimension of PC2 highlights the area dorsal of the VTA, as well as the medial aspect of the VTA (<xref rid="fig2" ref-type="fig">Figure 2D</xref>), while those corresponding to the negative dimension highlight the ventrolateral aspect of the ventral midbrain, including the substantia nigra pars reticulata (SNr) (<xref rid="fig2" ref-type="fig">Figure 2E</xref>). These results are consistent with the medial-lateral projection gradient that principally divides the projections into the VTA, with inputs from the basal ganglia projecting to the lateral portion of the VTA and the habenula projecting to the medial portion<sup><xref ref-type="bibr" rid="c32">32</xref></sup>. As inputs from the MHb and LHb contribute positive weights to the PC2 axis and vGluT2-Cre brains have the most positive PC2 values, it suggests that most of the vGluT2-expressing cells in the VTA are located within the medial portion of the VTA. This is consistent with previous reports using immunohistochemistry and in situ hybridization<sup><xref ref-type="bibr" rid="c48">48</xref>,<xref ref-type="bibr" rid="c49">49</xref></sup>. In addition, the EP, ZI, and DCN all project predominantly to the red nucleus, and the cortex also innervates the red nucleus, which contains glutamatergic neurons and is located dorsal to the VTA (<xref rid="fig2" ref-type="fig">Figure 2D</xref>). While injections for our viral mapping studies targeted the VTA and most starter neurons were within the VTA, there were some starter neurons in vGluT2-Cre brains located in the red nucleus. In contrast, this was not the case in DAT-Cre brains<sup><xref ref-type="bibr" rid="c10">10</xref></sup>. As these starter populations were also largely spatially overlapping, the data indicate that inputs with biases onto glutamatergic cells target the dorsomedial aspect of the VTA, while those with a relative bias onto DA cells preferentially target the ventrolateral aspect of the VTA.</p>
<p>While PCA is particularly useful due to the interpretability of the weights of the PCs, it cannot capture non-linear relationships in high-dimensional data, which are common in complex systems like in neuroscience. To examine the overall relationship of input patterns between DAT-Cre, GAD2-Cre, and vGluT2-Cre cell populations, we performed a second analysis on inputs from each population using Uniform Manifold Approximation and Projection, UMAP, which can capture more complex relationships than PCA. We found that DAT-Cre and GAD2-Cre brains were the most separated in UMAP space, with vGluT2-Cre brains located between them (<xref rid="fig2" ref-type="fig">Figure 2F</xref>). This is consistent with the overlap in neurotransmitters released by these cells: cells expressing DA markers such as tyrosine hydroxylase (TH) and traditional GABAergic markers such as GAD2 are nearly mutually exclusive, while there is considerable overlap between cells expressing DA markers and glutamatergic markers, as well as cells expressing GABAergic markers and glutamatergic markers<sup><xref ref-type="bibr" rid="c10">10</xref>,<xref ref-type="bibr" rid="c12">12</xref>,<xref ref-type="bibr" rid="c50">50</xref>–<xref ref-type="bibr" rid="c52">52</xref></sup>. Note that while DA neurons have been found to co-transmit DA and GABA<sup><xref ref-type="bibr" rid="c53">53</xref>,<xref ref-type="bibr" rid="c54">54</xref></sup>, this occurs through a non-canonical GABA synthesis pathway, and therefore DA cells do not express typical markers of GABAergic cells, such as GAD2, used to define the Cre line in our study.</p>
<p>Since individual UMAP embeddings are stochastic depending on initial seeding conditions, we examined the average Euclidian distance between pairs of brains in 20 UMAP embeddings and plotted the averaged results as a correlogram. This showed that DAT-Cre and vGluT2-Cre brains were more like one another, and the GAD2-Cre brains were the most distinct from the other conditions (<xref rid="fig2" ref-type="fig">Figure 2G</xref>). These results are thus consistent with the known neurochemical overlap between these cells and indicate that DAT-Cre and vGluT2-Cre label more overlapping cells with each other than with GAD2-Cre. In sum, these results serve to demonstrate that we can recapitulate the locations of different neurochemically-defined cells in the VTA based on PCA and projection portraits based on information from RABV input mapping data. They also provide a validation of our approach for dissecting the relationships between input patterns and different cell types within the VTA, as the conclusions about the relationship between input regions and cell types agree with other studies using different, complementary methodologies.</p>
</sec>
<sec id="s3b">
<title>A single injection of an addictive drug changes brain-wide input patterns to VTA<sup>DA</sup> cells</title>
<p>With our dimensionality reduction approaches validated on our cell type-specific RABV data, we next applied them to examining how addictive drugs may alter VTA input patterns. We first assessed whether the psychoactive but non-addictive fluoxetine altered brain-wide input patterns relative to saline-injected mice. We found no clear differences in inputs between these conditions, and they overlapped completely in PC space – with no significant differences in PC1, PC2, or PC3 between the saline and the fluoxetine brains (p &gt; 0.05 for PC1-3) - indicating fluoxetine did not alter brain-wide input patterns to VTA<sup>DA</sup> cells (<xref rid="fig3" ref-type="fig">Figure 3A-F</xref>). We therefore combined these groups for additional statistical power and tested whether a single administration of one of several addictive drugs caused changes in brain-wide input patterns to VTA<sup>DA</sup> cells, first considered as a single group. When comparing combined controls to the drugs group, we observed a statistically significant difference in input patterns, including a reduction in inputs from the DStr and elevation in inputs from the GPe following drug injection (<xref rid="fig3" ref-type="fig">Figure 3G</xref>). In order to more fully assess which input sites may differentiate the control- versus drug-treated groups, we again used PCA (<xref rid="fig3" ref-type="fig">Figure 3H-I</xref>). There was no significant difference between drugs and controls in PC1 (p = 0.78; <xref rid="fig3" ref-type="fig">Figure 3J</xref>). The differences in PC2 and PC3 were statistically significant: as we observed visually, the control group’s PC2 and PC3 values were significantly different from the drug group’s PC2 and PC3 values (p = 0.0009 and p = 0.024 for PC2 and PC3, respectively; <xref rid="fig3" ref-type="fig">Figure 3K-L</xref>). The positive axis of PC2, which was enriched in drug-treated brains, was driven by inputs from EAM, EP, GPe, LH, and PBN, while the negative axis was driven by the NAcMed, NAcCore, DStr, septum, and MHb (<xref rid="fig3" ref-type="fig">Figure 3M</xref>). Notably, the most negative weights for PC2, namely the NAcMed, NAcCore, DStr, septum, and MHb are all reduced in drug-treated brains (<xref rid="fig3" ref-type="fig">Figure 3G</xref>). Conversely, the most positive weights, namely the EAM, EP, GPe, LH, and PBN, are all increased in drug-treated brains (<xref rid="fig3" ref-type="fig">Figure 3G</xref>). Therefore, while PCA allows us to observe trends consistent with traditional methods, we can also observe the relationship between the percentage of inputs among different brains, and also identify relationships that are not immediately apparent in the data when presented as bar graphs. For example, while the BNST, CeA, and ZI do not show clear differences in control vs. drug-treated brains in the bar graphs, they are all positive weights in PC2 and thus, likely change in concert with regions such as the GPe and PBN (<xref rid="fig3" ref-type="fig">Figure 3G-M</xref>).</p>
    <p>Importantly, unlike traditional bar graph approaches, PCA allows us to isolate technical variation from the experiments, enabling us to focus more clearly on changes induced by the relevant variable, here treatment with a control substance or addictive drug. For example, PC1 does not distinguish control vs. drug-treated brains (<xref rid="fig3" ref-type="fig">Figure 3H, J</xref>), indicating this variable was inherent to the way the experiment was performed and not related to drug or control treatment. The strongest negative weights for PC1 were the NAcLat, NAcCore, DStr, and GPe, while the strongest positive weights for PC1 were the VP, PO, LHb, and DR (<xref rid="fig3" ref-type="fig">Figure 3M</xref>). This is consistent with connectivity differences along the medial-lateral axis of the VTA, which underlies many of the connectivity differences to different VTA<sup>DA</sup> subpopulations<sup><xref ref-type="bibr" rid="c7">7</xref>,<xref ref-type="bibr" rid="c10">10</xref>,<xref ref-type="bibr" rid="c32">32</xref></sup>. To assess whether PC1 may reflect differences the location of starter cells in the VTA, we first assessed whether there was a systematic difference in starter cell location between conditions. We noted a high level of overlap in starter cell distribution between conditions (<xref rid="fig4" ref-type="fig">Figure 4A</xref>, <xref ref-type="fig" rid="figs2">S2</xref>), indicating that this alone likely did not explain differences between control and drug-treated groups. We then assessed whether brain to brain variation in starter cell distribution could explain the effects observed along PC1.</p>
<p>We therefore colored each point in PC space according to the assessed center of injection for each experiment. We noted a clear medial-lateral gradient along PC1, but not PC2 or PC3 (<xref rid="fig4" ref-type="fig">Figure 4B-C</xref>). To test the significance of this relationship, we performed linear regression analysis, comparing the x-coordinate of the injection center relative to location along PC1, PC2, or PC3 for each brain. We observed a highly significant positive correlation with PC1, a slightly positive but non-significant correlation with PC2, and no correlation for PC3 (<xref rid="fig4" ref-type="fig">Figure 4D-F</xref>). These results show that PC1 reflects variation in the injection site within the VTA, while PC2 reflects changes induced by addictive drugs, allowing us to isolate the changes in input connectivity induced by administration of a single addictive drug.</p>
    <p>With our integrative methodology validated on cell type-specific RABV data and demonstrating that addictive drugs alter brain-wide input patterns to VTA<sup>DA</sup> cells, we applied our approaches to explore the effects of each drug specifically, as well as potential effects of the 2x use of the K/X anesthetic mixture. We first asked two questions: 1) How do injections of different addictive drugs change the connectivity patterns onto VTA cells? 2) How do these potential drug-induced differences relate to differences between unique cell types in the VTA? To answer these, we first assessed experiments with ten separate experimental conditions: 2 conditions of GAD2-Cre mice, and 8 conditions of DAT-Cre mice. The GAD2-Cre mice were all anesthetized with isoflurane and administered either saline or cocaine one day prior to RABV injection. The DAT-Cre mice were given either isoflurane or K/X-based anesthesia. The K/X-anesthetized mice were administered saline. The isoflurane-anesthetized mice were administered either saline, fluoxetine, amphetamine, cocaine, methamphetamine, morphine, or nicotine. RABV mapping was performed from targeted VTA cells in all cases, and the brain-wide inputs were quantified. We then performed PCA on the combined RABV tracing datasets, which showed that brains from GAD2-Cre mice were in the positive dimension of PC1, while those from DAT-Cre mice were in the negative dimension (<xref rid="fig5" ref-type="fig">Figure 5A</xref>), regardless of the substance administered. This difference in PC1 was highly statistically significant (One-way ANOVA p &lt; 0.0001; all conditions pairwise comparisons with GAD2-Cre, multiple comparisons adjusted p &lt; 0.0001; <xref rid="fig5" ref-type="fig">Figure 5B</xref>). The positive dimension of PC1 received contributions from largely the same sets of regions as in the previous analysis of DAT-Cre, GAD2-Cre, and vGluT2-Cre brains, which included the BNST, EP, ZI, CeA, as well as the DCN (<xref rid="fig5" ref-type="fig">Figure 5C</xref>, <xref ref-type="fig" rid="fig1">1G</xref>). Given that the same set of brain regions differentiated DAT-Cre and GAD2-Cre brains along PC1 in both datasets, this suggests that the intrinsic differences in inputs to different cell populations in the VTA are more pronounced than differences induced by addictive drugs, fluoxetine, or the method of anesthesia. Notably, these patterns were unlikely to be obtained by chance; scrambling the sample identity and percentage of RABV-labeled cells in each input site resulted in groups that overlapped in both PCA and UMAP space (<xref ref-type="fig" rid="figs3">Figure S3</xref>).</p>
    <p>To specifically explore potential drug-induced differences in input labeling onto VTA<sup>DA</sup> cells, we removed GAD2-Cre brains from the dataset. Results and representative images are shown in <xref rid="fig5" ref-type="fig">Figure 5D-E</xref>. In PCA analyses of these brains only, PC1 and PC3 largely failed to differentiate the conditions, with no significant differences observed, while PC2 significantly differentiated the conditions (One-way ANOVA p = 0.0093; saline vs. drugs multiple comparisons adjusted p = 0.034; <xref rid="fig5" ref-type="fig">Figure 5F-J</xref>). The most negative weights to PC1 were contributed by the basal ganglia inputs (<xref rid="fig5" ref-type="fig">Figure 5K</xref>) that project to the SNr, located ventrolaterally to the VTA (<xref rid="fig6" ref-type="fig">Figure 6A</xref>) while positive contributors came from brain regions that projected more medially (LHb, MHb, dorsal raphe (DR)) and centrally to the VTA (ventral pallidum (VP), PO, extended amygdala area (EAM), paraventricular nucleus of the hypothalamus (PVH), and LH) (<xref rid="fig5" ref-type="fig">Figure 5K</xref>, <xref ref-type="fig" rid="fig6">6B</xref>). This is consistent with a gradient along the medial-lateral axis<sup><xref ref-type="bibr" rid="c32">32</xref></sup>. As it did not differentiate the conditions, this axis likely represents experimental variations in the location of starter cell populations within the VTA<sup><xref ref-type="bibr" rid="c7">7</xref>,<xref ref-type="bibr" rid="c10">10</xref>,<xref ref-type="bibr" rid="c32">32</xref></sup>. The regions with the largest positive contribution to PC2 included the EAM, parabrachial nucleus (PBN), DR, EP, and LH, with lesser contributions from the GPe, DCN, ZI, CeA, and BNST (<xref rid="fig5" ref-type="fig">Figure 5K</xref>, <xref ref-type="fig" rid="fig6">6C</xref>). These regions were over-represented in animals treated with a single administration of an addictive drug. Notably, this group of inputs contained brain regions that are involved in the brain’s stress response such as the PBN, EAM, CeA, and BNST, and have been implicated in drug-induced behaviors<sup><xref ref-type="bibr" rid="c55">55</xref>,<xref ref-type="bibr" rid="c56">56</xref></sup>. For example, we recently showed the importance of the GPe in conditioned place preference and locomotor sensitization and the BNST in drug-induced withdrawal<sup><xref ref-type="bibr" rid="c15">15</xref>,<xref ref-type="bibr" rid="c25">25</xref></sup>. The regions with the largest negative contribution to PC2 included the NAcMed, NAcCore, DStr, Septum, and MHb (<xref rid="fig5" ref-type="fig">Figure 5K</xref>, <xref ref-type="fig" rid="fig6">6D</xref>). These regions were underrepresented in animals given a single administration of an addictive drug. These results together demonstrate that addicive drugs cause long-lasting changes in input populations to DA cells, and that we can identify which sets of inputs distinguish drug-treated vs. control-treated brains. These changes may be functionally important, as we previously demonstrated the functional role of two inputs, the GPe and BNST, that we identified as differing between drug- treated and control conditions<sup><xref ref-type="bibr" rid="c25">25</xref>,<xref ref-type="bibr" rid="c57">57</xref></sup>.</p>
<p>Lastly, we wanted to explore the overall relationship between input changes induced by different drugs. As before, we used UMAP to explore the higher-level organization of these conditions to compare the relationship of holistic input patterns between groups. We found that the mice anesthetized with isoflurane and treated with saline overlapped with the isoflurane-anesthetized, fluoxetine-treated group and the K/X-anesthetized and saline-treated group, but segregated from animals treated with the addictive drugs - psychostimulants, morphine, and nicotine (<xref rid="fig6" ref-type="fig">Figure 6E</xref>). Our analysis of the relationships between individual conditions, generated using the Euclidian distances between points in 20 UMAP embeddings as before, demonstrated that the expected control conditions formed a cluster (saline, fluoxetine) distinct from the other groups. Interestingly, the K/X-anesthetized animals were more closely associated with the mice treated with addictive drugs, in particular morphine, than with controls (<xref rid="fig6" ref-type="fig">Figure 6F</xref>). This suggests that addictive drugs cause similar changes in brain-wide input patterns to one another in DAT-Cre mice, and that input patterns in K/X-anesthetized animals more closely resemble morphine-treated mice than saline- treated mice. This indicates that the method of anesthesia, either using isoflurane or K/X, results in different patterns of input labeling. Given the similarity of input patterns in K/X-anesthetized mice to isoflurane-anesthetized mice treated with an addictive drug but not saline, we suspect that two doses of K/X-anesthesia as is required for RABV circuit mapping experiments triggers changes in input patterns in rodent brains that last at least the five-day duration of these experiments.</p>
</sec>
<sec id="s3c">
<title>Anesthetic doses of K/X cause long-lasting changes in inputs to VTA<sup>DA</sup>→NAcLat and VTA<sup>DA</sup>→Amygdala cells</title>
<p>To examine how differences in anesthesia methods may impact brain-wide input patterns, we performed some more targeted comparisons. When comparing only two groups using PCA – isoflurane-anesthetized animals to K/X-anesthetized animals – these conditions completely segregated (<xref rid="fig7" ref-type="fig">Figure 7A</xref>). While the difference in PC1 was not quite significant (p = 0.086), the difference in PC2 was significant (p = 0.037). This separation was driven by positive weights from the VP, PO, EAM, PVH, LH, and PBN along PC1, which were more strongly represented in the K/X-anesthetized mice and whose combined projection portrait broadly targets the VTA (<xref rid="fig7" ref-type="fig">Figure 7A-D</xref>), and the NAcLat, DStr, GPe, and PVH along PC2, which were also more strongly represented in the K/X-anesthetized mice whose combined projection portrait targets ventrolateral to the VTA (<xref rid="fig7" ref-type="fig">Figure 7A-C, E</xref>). A similar separation of conditions was observed using UMAP (<xref rid="fig7" ref-type="fig">Figure 7F</xref>).</p>
<p>Next, we wanted to assess which VTA<sup>DA</sup> cells may be impacted by whether the animals received isoflurane or K/X-based anesthesia. To test this, we performed cell type-specific Tracing of the Relationship between Inputs and Outputs (cTRIO) for each of four different VTA<sup>DA</sup> subpopulations: those projecting to the NAcMed, NAcLat, Amygdala, or mPFC, and receiving K/X anesthesia and saline, isoflurane and saline, or isoflurane and cocaine. The differences in input patterns between conditions were most pronounced for VTA<sup>DA</sup>→NAcLat cells, where the isoflurane- and K/X-treated groups segregated (<xref rid="fig7" ref-type="fig">Figure 7G-H</xref>). Groups appeared to differ along both PC1 and PC2, though differences in PC2 were not statistically significantly different. K/X-treated brains were characterized by lower PC1 values which received contributions principally from the anterior cortex, NAcMed, NAcLat, NAcCore, septum, PVH, and MHb, as well as higher PC2 values which received contributions from the VP, PO, EAM, LHb, and LH (PC1, One-way ANOVA p = 0.0003, saline vs. cocaine multiple comparisons adjusted p = 0.011, K/X vs. cocaine multiple comparisons adjusted p = 0.0002; <xref rid="fig7" ref-type="fig">Figure 7G, I-K</xref>). The following comparisons in PC1 were statistically significant: cocaine versus isoflurane controls (p = 0.011) and cocaine versus K/X anesthesia (p = 0.001) (<xref rid="fig7" ref-type="fig">Figure 7G</xref>). Notably, K/X, saline-treated mice and isoflurane, cocaine-treated mice segregate from one another in PCA space, indicating that the K/X-induced changes are distinct from those induced by cocaine (<xref rid="fig7" ref-type="fig">Figure 7G-I</xref>). The similarity in projection portraits for weights that contribute more to the K/X-treated group in VTA<sup>DA</sup>→NAcLat (<xref rid="fig7" ref-type="fig">Figure 7J-K</xref>) and all VTA<sup>DA</sup> neurons (<xref rid="fig7" ref-type="fig">Figure 7D-E</xref>) suggests that largely overlapping DA cells may be targeted for each set of experiments and is consistent with the observation that VTA<sup>DA</sup>→NAcLat neurons comprise the majority of VTA<sup>DA</sup> neurons, as noted in previous studies<sup><xref ref-type="bibr" rid="c7">7</xref>,<xref ref-type="bibr" rid="c10">10</xref></sup>. As with all VTA<sup>DA</sup> cells, similar results were observed for VTA<sup>DA</sup>→NAcLat cells in both in PCA and UMAP space (<xref rid="fig7" ref-type="fig">Figure 7L</xref>). These results thus serve as another proof of principle of the reliability of our approach to pull out similar results from different datasets.</p>
    <p>In addition to VTA<sup>DA</sup>→NAcLat cells, we observed some segregation of isoflurane and K/X-treated conditions in VTA<sup>DA</sup>→Amygdala cells (<xref rid="fig7" ref-type="fig">Figure 7M-P</xref>). The lack of clear differentiation in PCA space, with only PC3 showing significant differences between the isoflurane control group and K/X anesthesia (One-way ANOVA p = 0.014, saline vs. K/X multiple comparisons adjusted p = 0.0078; <xref ref-type="fig" rid="figs4">Figure S4</xref>) makes it difficult to interpret which input sites may be contributing to the differentiation in conditions that we observed. In the VTA<sup>DA</sup>→NAcMed and VTA<sup>DA</sup>→mPFC subpopulations, the separation between isoflurane-saline, isoflurane-cocaine, and K/X-saline conditions was much less pronounced (<xref ref-type="fig" rid="figs5">Figure S5</xref>), and not significant; indeed, similar separations were observed by chance (<xref ref-type="fig" rid="figs6">Figure S6</xref>). Notably, when considering inputs to all VTA<sup>DA</sup> cells, the projection portraits that indicate the inputs most highly elevated or depressed in K/X- treated mice highlight either the entire VTA, or the ventrolateral aspect of the VTA (<xref rid="fig7" ref-type="fig">Figure 7D-E</xref>).</p>
<p>These projections are consistent with the locations of the VTA<sup>DA</sup>→Amygdala and VTA<sup>DA</sup>→NAcLat cells, respectively, within the VTA. In contrast, the portraits do not highlight the medial or ventromedial aspects of the VTA, which is the location of VTA<sup>DA</sup>→mPFC and VTA<sup>DA</sup>→NAcMed cells<sup><xref ref-type="bibr" rid="c32">32</xref>,<xref ref-type="bibr" rid="c58">58</xref></sup>. These results together indicate that K/X anesthesia impacts inputs that preferentially target VTA<sup>DA</sup>→NAcLat or VTA<sup>DA</sup>→Amygdala cells.</p>
</sec>
<sec id="s3d">
<title>Exploring gene expression patterns that predict changes in RABV input labeling</title>
<p>We next wanted to explore if drug-induced changes in input connectivity might be related to gene expression profiles in cells located in the input sites. To do this, we calculated the correlation of gene expression data from the Allen Gene Expression Atlas (AGEA) with the difference (<xref rid="fig8" ref-type="fig">Figure 8</xref>) between RABV-labeled inputs labeled in each region in experimental conditions and isoflurane/saline-treated controls. Notably, the AGEA data are from all cells in the input regions and are not limited to those projecting to the VTA and show only baseline gene expression patterns and not those following drug administration. Nonetheless, these analyses can be a valuable starting point in associating spatial gene expression data with patterns of RABV-labeled inputs from VTA<sup>DA</sup> cells. After filtering AGEA data for only high-quality experiments, we were left with 4,283 genes to which we could calculate correlations within our 22 input brain regions of interest.</p>
    <p>We first identified genes or pathways that may be linked to elevations or depressions in RABV labeling for each condition. We selected genes that were highly positively or negatively correlated to differences between 1) isoflurane-saline controls and 2) isoflurane- psychostimulant, morphine, nicotine, or fluoxetine, or 3) K/X-saline mice. We used the top 50 genes in the AGEA data that were either positively or negatively correlated (Spearman’s ρ) to differences in RABV labelling and performed gene ontology (GO) analyses. Starting with addictive drugs in aggregate, the 50 most positively correlated genes (Spearman’s ρ &gt; 0.47, p &lt; 0.05) were most significantly associated with inhibitory ligand-gated chloride channels (<xref rid="fig8" ref-type="fig">Figure 8A</xref>), suggesting that higher basal expression of these genes may be related to larger changes in connectivity induced by a single dose of an addictive drug. Conversely, there were many more genes that were strongly negatively correlated to drug-induced changes in RABV labeling. The 50 most negatively correlated genes (Spearman’s ρ &lt; -0.68, p &lt; 0.001) were most closely associated with negative regulation of long-term synaptic potentiation (<xref rid="fig8" ref-type="fig">Figure 8B</xref>), suggesting that regulation of synaptic plasticity in input cell populations may be a key indicator of the likelihood of an addictive drug altering RABV input labeling. We repeated this analysis of the top 50 genes with each individual drug: cocaine, methamphetamine, amphetamine, morphine, and nicotine. In addition to findings in aggregate, other interesting classes of genes that were negatively associated (Spearman’s ρ &lt; -0.50, p &lt; 0.05) with individual drug-induced changes in RABV labeling include regulation of synapse structural plasticity (methamphetamine), regulation of calcium (Ca<sup>2+</sup>) ion transport (nicotine), cellular response to Ca<sup>2+</sup> ions (cocaine), and regulation of potassium ion transporters (nicotine) (<xref ref-type="fig" rid="figs7">Figure S7</xref>), which relate to synaptic and cellular processes of plasticity and intrinsic excitability. There were fewer than 50 genes that were significantly positively correlated, but the top 50 genes (Spearman’s ρ &gt; 0.36, p &lt; 0.12) were associated with terms including anion channels (cocaine, amphetamine, methamphetamine) and syntaxin binding (cocaine, amphetamine, nicotine) (<xref ref-type="fig" rid="figs8">Figure S8</xref>). We also explored which gene expression patterns may be related to input changes driven by K/X anesthesia. Anion channel activity, particularly GABA receptor expression, again shows up as one of the most significant associations to the top 50 most positively correlated genes (Spearman’s ρ &gt; 0.37, p &lt; 0.10) (<xref rid="fig8" ref-type="fig">Figure 8C</xref>), while negatively correlated genes were associated with a variety of metabolic processes (<xref rid="fig8" ref-type="fig">Figure 8D</xref>). Notably, these gene expression patterns were not correlated with input changes induced by fluoxetine (<xref ref-type="fig" rid="figs9">Figure S9</xref>).</p>
    <p>To further assess which classes of genes were the most closely related to the differences in drug- evoked RABV labeling relative to controls, we performed linear regressions of the ratios of RABV labeling in experimental vs. control conditions relative to the mean of the log normalized expression of AGEA RNA <italic>in situ</italic> hybridization data for a particular class of genes. We observed an overall significant and slightly negative correlation between the RABV labeling ratio and the gene expression mean (r = -0.30, p = 2.1 x 10<sup>-3</sup>) for all 4,283 genes (<xref ref-type="fig" rid="figs10">Figure S10A</xref>). This genome- wide negative correlation is a useful reference to compare to correlation coefficients of subsets of genes. Among the gene expression classes that we examined, the most significant association was between the change in RABV-labeled inputs and ion channel gene expression (r = -0.56, p = 1.3 x 10<sup>-9</sup>; <xref rid="fig9" ref-type="fig">Figure 9A</xref>), consistent with our results from GO analyses. The next most significant classes were neurotransmitter receptors (r = -0.46, p = 1.9 x 10<sup>-6</sup>) and synapses (r = -0.42, p = 1.6 x 10<sup>-5</sup>), followed by genes that have been linked to SUDs through Genome-Wide Association Studies (GWAS; r = -0.33, p = 7.7 x 10<sup>-4</sup>) as well as endo/exocytosis genes (r = -0.30, p = 2.3 x 10<sup>-3</sup>). Each of the above relationships showed a negative correlation of RABV ratios with gene expression (<xref rid="fig9" ref-type="fig">Figure 9B-C</xref>, <xref ref-type="fig" rid="figs10">S10B-C</xref>). Except for endo/exocytosis genes, each class had a more negative, significant correlation than our genome-wide reference. As a further comparison, we observed that the relationships between RABV labeling ratios and gene classes that are likely irrelevant to RABV labeling, such as mitochondrial genes (r = -0.24, p = 1.4 x 10<sup>-2</sup>), sugar transporters (r = -0.26, p = 1.0 x 10<sup>-2</sup>), and tumor-associated genes (r = -0.18, p = 7.0 x 10<sup>-2</sup>) were weaker and less significant than our classes of interest (<xref ref-type="fig" rid="figs10">Figure S10D-F</xref>).</p>
    <p>As the class of ion channel genes was the most strongly correlated to drug-induced differences in RABV-labeled input patterns, we assessed which ion channels are most closely linked to RABV labeling differences between conditions. The most significant relationship was between Ca<sup>2+</sup> channel genes (r = -0.57, p = 4.4 x 10<sup>-</sup><sup><xref ref-type="bibr" rid="c10">10</xref></sup>), followed by Cl<sup>-</sup> (r = -0.39, p = 6.1 x 10<sup>-5</sup>), K<sup>+</sup> (r = -0.30, p = 2.9 x 10<sup>-3</sup>), and Na<sup>+</sup> channels (r = -0.11, p = 0.30; <xref rid="fig9" ref-type="fig">Figure 9D-G</xref>). The expression levels of these channels, in particular Ca<sup>2+</sup> channels, are linked to regulating a variety of cellular processes, including immediate early gene expression networks as well as cellular excitability. Ligand-gated channels (r = -0.40, p = 4.1 x 10<sup>-5</sup>) were more strongly related with RABV labeling than voltage- gated ion channels (r = -0.33, p = 7.4 x 10<sup>-4</sup>) or other types of ion channels (r = -0.13, p = 0.21; <xref ref-type="fig" rid="figs10">Figure S10G-I</xref>). Among the ligand-gated channels, the glutamate receptors were the most strongly correlated (r = -0.49, p = 3.1 x 10<sup>-7</sup>; <xref rid="fig9" ref-type="fig">Figure 9H</xref>). The next most strongly correlated gene classes were acetylcholine receptors (r = -0.36, p = 2.4 x 10<sup>-4</sup>), GABA receptors (r = -0.31, p = 1.8 x 10<sup>-3</sup>), and glycine receptors (r = 0.32, p = 1.4 x 10<sup>-3</sup>) (<xref rid="fig9" ref-type="fig">Figure 9I-K</xref>). Notably, glycine receptors were the only class of genes that we analyzed that was positively correlated with RABV labeling. Similar patterns were observed for K/X anesthetized mice (<xref ref-type="fig" rid="figs11">Figure S11</xref>), but not with isoflurane- anesthetized, fluoxetine-treated mice (<xref ref-type="fig" rid="figs12">Figure S12</xref>). These results together indicate that the basal expression levels of a variety of ion channels, particularly Ca<sup>2+</sup> and ligand-gated ion channels, may be related to driving elevations or depressions in RABV labeling following a single injection of a variety of addictive drugs, or K/X anesthesia.</p>
</sec>
<sec id="s3e">
<title>Functional validation of link between gene expression and RABV labeling</title>
    <p>As the correlation between RABV labeling ratios and Ca<sup>2+</sup> channel gene expression was negative, lower expression of Ca<sup>2+</sup> genes was linked to an elevation in drug-induced RABV input labeling. This relationship could be explained by several mechanisms. One, expression of Ca<sup>2+</sup> channel genes could be inhibitory towards the drug-induced change in RABV transmission. Alternatively, lower Ca<sup>2+</sup> channel gene expression levels could indicate more potential for a drug-induced rise in gene expression level. To start differentiating between these possibilities, we performed CRISPR-based gene expression modulation of the voltage-gated calcium ion channel <italic>Cacna1e</italic> using CRISPRi, which reduces gene expression through blocking DNA transcription without cutting DNA<sup><xref ref-type="bibr" rid="c59">59</xref></sup> (<xref rid="fig10" ref-type="fig">Figure 10A-B</xref>). <italic>Cacna1e</italic> was chosen as a test gene because it was one of the Ca<sup>2+</sup> channel genes included in <xref rid="fig9" ref-type="fig">Figure 9D</xref> that had a strong negative correlation with RABV labeling, and was strongly expressed in the nucleus accumbens<sup><xref ref-type="bibr" rid="c37">37</xref></sup> (<xref ref-type="fig" rid="figs13">Figure S13</xref>). Three different adeno-associated viruses (AAV) were co-injected into the NAcLat, an input site to the VTA, in DAT-Cre mice. These viruses expressed 1) Cre, 2) Cre-dependent dCas9, 3) a Cre-dependent small guide RNA (gRNA) targeting <italic>Cacna1e</italic>. A two AAV mixture lacking the AAV expressing the gRNA was used as a control. The three AAV experimental mix was administered into the NAcLat in one hemisphere, while the two AAV control mix was injected into the other hemisphere. During the same surgery, AAVs expressing Cre-dependent TVA-mCherry and RABV glycoprotein were bilaterally injected into the VTA, so that RABV mapping could be done in both hemispheres (<xref rid="fig10" ref-type="fig">Figure 10C-D</xref>). Because the NAcLat, NAcCore, and GPe unilaterally project to the VTA in the same hemisphere, and not the contralateral VTA<sup><xref ref-type="bibr" rid="c7">7</xref>,<xref ref-type="bibr" rid="c10">10</xref>,<xref ref-type="bibr" rid="c15">15</xref>,<xref ref-type="bibr" rid="c25">25</xref></sup>, the ratio of labeled inputs in these sites on a single hemisphere can be used to assess the relative labeling in the NAcLat in experimental and control conditions within each mouse.</p>
<fig id="fig10" position="float" orientation="portrait" fig-type="figure">
<label>Figure 10:</label>
<caption>
<title>Inhibition of <italic>Cacna1e</italic> expression in the NAcLat reduces RABV-labeled inputs from the NAcLat onto VTA<sup>DA</sup> cells.</title>
<p>(A) Schematic of viral injections performed. (B) Schematic of connectivity in relevant brain regions and explanation of the normalized input metric. (C) Representative image of fluorescence in starter cells in the VTA. Main image scale, 1 mm; inset scale, 100 μm. (D) Representative image of fluorescence in the NAcLat after either administration of no gRNA (left) or gRNA targeting <italic>Cacna1e</italic> (right). Main image scale, 1 mm; inset scale, 100 μm. (E) qPCR results showing slight inhibition of <italic>Cacna1e</italic> in the NAcLat. (F) Difference in RABV-labeled inputs after CRISPRi-mediated knockdown of <italic>Cacna1e</italic> compared to controls<sup><xref ref-type="bibr" rid="c15">15</xref></sup>, and no gRNA. The control conditions are based on previously published data where no AAVs were injected into NAcLat<sup>7</sup>.</p>
</caption>
<graphic xlink:href="520804v3_fig10.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>We first validated that our CRISPRi strategy reduced <italic>Cacna1e</italic> gene expression. We designed our gRNA to cause only a mild reduction in <italic>Cacna1e</italic> expression to more naturally mimic potential changes in gene expression. We found that our CRISPRi perturbation reduced gene expression by ∼20% (<xref rid="fig10" ref-type="fig">Figure 10E</xref>). This knockdown of <italic>Cacna1e</italic> in the NAcLat via CRISPRi resulted in decreased RABV-labeled inputs from the NAcLat compared to controls where the gRNA was not included (<xref rid="fig10" ref-type="fig">Figure 10F</xref>). These results indicate that reduced levels of <italic>Cacna1e</italic> likely lower the number of RABV-labeled inputs from the NAcLat, and directly link the levels of <italic>Cacna1e</italic> and RABV input labeling.</p>
</sec>
</sec>
<sec id="s4">
<title>Discussion</title>
<p>Here we explored the long-term consequences of a single injection of a variety of addictive drugs on the connectivity of VTA<sup>DA</sup> cells. We first confirmed that dimensionality reduction approaches could adequately differentiate the connectivity between different cell populations in the VTA, and showed which inputs differentiate DAergic, GABAergic, and glutamatergic cells in the VTA (<xref rid="fig1" ref-type="fig">Figures 1</xref>-<xref rid="fig2" ref-type="fig">2</xref>). We then showed that a variety of addictive drugs as well as K/X-based anesthesia trigger long-lasting changes in the brain-wide input patterns to VTA cells, which were clearly observable though less substantial than the differences onto different cell types or natural variation in starter cell location (<xref rid="fig3" ref-type="fig">Figures 3</xref>-<xref rid="fig6" ref-type="fig">6</xref>). We used our cTRIO method to identify DA cell type- specific changes induced by cocaine as well as K/X anesthesia, implicating the VTA<sup>DA</sup>→NAcLat and VTA<sup>DA</sup>→Amygdala cells as those exhibiting the most substantial input changes (<xref rid="fig7" ref-type="fig">Figure 7</xref>).</p>
<p>We then explored intrinsic gene expression patterns throughout the brain that relate to the elevation or depression in RABV labeling by different drugs, finding that expression levels of ion channels, neurotransmitter receptors, and synapse-related genes were all significantly negatively correlated with RABV input labeling ratios, with Ca<sup>2+</sup> channels and glutamate receptors being the most strongly correlated (<xref rid="fig8" ref-type="fig">Figures 8</xref>-<xref rid="fig9" ref-type="fig">9</xref>). We then demonstrated the causative role of one calcium channel gene, <italic>Cacna1e</italic>, in influencing RABV input mapping efficiency (<xref rid="fig10" ref-type="fig">Figure 10</xref>).</p>
<sec id="s4a">
<title>Addictive drugs induce changes in connectivity onto VTA<sup>DA</sup> neurons from common and distributed input populations throughout the brain</title>
<p>Using dimensionality reduction approaches we differentiated the input patterns to different VTA cells (<xref rid="fig1" ref-type="fig">Figures 1</xref>-<xref rid="fig2" ref-type="fig">2</xref>) and showed that these differences were larger than the differences in inputs from the same cell populations in animals given an addictive drug vs. saline (<xref rid="fig5" ref-type="fig">Figure 5A</xref>). Notably, these differences were unique from those triggered by the psychoactive but non-addictive substances fluoxetine and K/X (<xref rid="fig5" ref-type="fig">Figure 5</xref>). Differences were apparent on the 2<sup>nd</sup> PC axis, which were driven by positive weights from the GPe, EP, EAM, LH, ZI, DR, and PBN, regions that showed elevated connectivity in drug-treated mice. Many of these regions have been implicated in cocaine addiction<sup><xref ref-type="bibr" rid="c60">60</xref>–<xref ref-type="bibr" rid="c63">63</xref></sup>. While these drug-induced differences in input labeling were less substantial than intrinsic cell type connectivity differences (<xref rid="fig5" ref-type="fig">Figure 5A</xref>) or differences in starter cell location (<xref rid="fig4" ref-type="fig">Figure 4</xref>), these differences were more apparent when using dimensionality reduction methods such as PCA and UMAP. That different cell types exhibit larger differences in input patterns than the same cell type with and without drug administration is perhaps not surprising, as different populations of cells may receive different sets of inputs from one another, and these are likely more stable across experiments than the differences in connectivity triggered following a single exposure to an addictive drug. The same is likely true for spatial gradients, which we determined to be a major source of variation in RABV inputs to the VTA<sup><xref ref-type="bibr" rid="c32">32</xref></sup>. Notably, the minor differences in starter cell location are likely not a technical concern specific to our study, but rather inherent to all RABV mapping experiments that rely on intracranial injections, as a small amount of biological or technical variation is to be expected. The PCA approach we employ here, however, can better isolate these effects than traditional bar graph approaches and thus enable clearer observation of the effect of the relevant variable being tested, here effects of a single drug administration (or K/X anesthesia) on the input connectivity to VTA<sup>DA</sup> cells. Importantly, these analyses may provide important insight into the circuit mechanisms underlying SUDs; for example, the GPe, LH, and PBN show up as high on PC2 from brains of mice treated with an addictive drug (<xref rid="fig5" ref-type="fig">Figure 5K</xref>). We showed the importance of the GPe in behaviors elicited by cocaine<sup><xref ref-type="bibr" rid="c15">15</xref>,<xref ref-type="bibr" rid="c57">57</xref></sup>, the importance of the LH, in particular neuropeptides such as orexin, melanin-concentrating hormone in reward learning and memory is well-known<sup><xref ref-type="bibr" rid="c64">64</xref>–<xref ref-type="bibr" rid="c67">67</xref></sup>, and the PBN, while much less studied in the context of addiction, is involved in regulating negative emotions, pain, and aversion, and has begun to be implicated in SUD-related behaviors<sup><xref ref-type="bibr" rid="c68">68</xref>,<xref ref-type="bibr" rid="c69">69</xref></sup>. Thus, our data could be used to generate new hypotheses about connections that are yet-unstudied but play important roles in addiction.</p>
<p>The results in this study further confirm our previous observations that a single exposure to a variety of addictive drugs triggers long-lasting changes in inputs to VTA<sup>DA</sup> neurons. Our interpretation of these data is that the changes are largely being driven by a change in the activity of input cells, as we have shown using fiber photometry and slice electrophysiology in three separate studies<sup><xref ref-type="bibr" rid="c15">15</xref>,<xref ref-type="bibr" rid="c16">16</xref>,<xref ref-type="bibr" rid="c70">70</xref></sup>. However, we have not confirmed this to be true for all cases. As a single exposure to a variety of addictive drugs alters the strength of both excitatory and inhibitory inputs in the VTA<sup><xref ref-type="bibr" rid="c5">5</xref>,<xref ref-type="bibr" rid="c20">20</xref>–<xref ref-type="bibr" rid="c22">22</xref></sup>, we cannot rule out that changes in synapse number or strength may also influence the observed connectivity results.</p>
</sec>
<sec id="s4b">
<title>Ketamine/xylazine anesthesia alters the input landscape of VTA<sup>DA</sup> cells</title>
<p>Animals anesthetized with a K/X mixture showed a different pattern of input labeling to VTA<sup>DA</sup> cells than animals anesthetized with isoflurane (<xref rid="fig7" ref-type="fig">Figure 7A-B</xref>). While we cannot perform RABV mapping on unanesthetized mice, making it impossible to definitively define which mode of anesthesia, or both, alters RABV input patterns we suspect that isoflurane anesthesia has minimal effect on the brain-wide inputs to VTA<sup>DA</sup> cells. This is largely because animals treated with an addictive drug with isoflurane anesthesia look more like those receiving K/X-saline than isoflurane-saline animals (<xref rid="fig5" ref-type="fig">Figures 5</xref>-<xref rid="fig6" ref-type="fig">6</xref>). In addition, ketamine is a drug with known addictive liability<sup><xref ref-type="bibr" rid="c71">71</xref>–<xref ref-type="bibr" rid="c74">74</xref></sup>. While the anesthetic doses used here (100 mg/kg) are well above the doses used recreationally (∼1 mg/kg), the changes that we observed with K/X anesthesia may be related to the addictive liability of ketamine. Interestingly, the K/X-induced input changes were most similar to those induced by 10 mg/kg of morphine (<xref rid="fig6" ref-type="fig">Figure 6F</xref>). Antidepressant doses of ketamine may work in part via the opioid system; indeed, it has been known for some time that ketamine binds to the mu opioid receptor<sup><xref ref-type="bibr" rid="c75">75</xref>–<xref ref-type="bibr" rid="c78">78</xref></sup>, and it was more recently shown that the opioid antagonist naltrexone blocks the antidepressant effects of ketamine<sup><xref ref-type="bibr" rid="c79">79</xref>,<xref ref-type="bibr" rid="c80">80</xref></sup>. Given that anesthetic doses of ketamine (100 mg/kg) are roughly 10 times higher than antidepressant doses of ketamine (∼10 mg/kg), K/X anesthesia almost certainly engages the opioid system.</p>
</sec>
<sec id="s4c">
<title>Relationship of gene expression with the extent of drug-induced RABV input labeling</title>
<p>Gene expression patterns in the mouse brain are correlated with the extent of elevations and depressions of RABV labeling induced by one of several addictive drugs. We observed a slightly negative correlation of RABV labeling changes with the overall level of gene expression across the brain. We are not sure of the implications of this negative correlation, though it could suggest that if initial gene expression levels are lower, it leaves a higher potential for experience-induced elevations. We observed significant negative correlations of RABV labeling changes induced by addictive drugs with the levels of expression of ion channel genes, neurotransmitter receptor- related genes, and synapse-related genes. These results and our experiments demonstrating the functional impact of downregulating <italic>Cacna1e</italic> for RABV input labeling (<xref rid="fig10" ref-type="fig">Figure 10</xref>) indicate that the expression levels of these genes could be used as predictive biomarkers of which regions are likely to undergo drug-induced changes in connectivity to VTA<sup>DA</sup> cells. They also suggest that the expression levels of these gene classes are related to the drug-induced changes in RABV labeling.</p>
<p>While the AGEA is a useful resource for relating spatial gene expression information to our RABV mapping datasets, there are notable limitations. First, the AGEA dataset is not as quantitatively rigorous as modern single nucleus RNA sequencing or spatial transcriptomic datasets. Nonetheless, we believe that the overall patterns of high and low expression, especially when considered among classes of genes as was performed here, can still be informative. Furthermore, the AGEA dataset provides a static picture of gene expression levels throughout the brain, and thus does not account for potential changes in gene expression levels triggered by administration of one of the drugs used in this study. Third, the AGEA dataset considers expression levels in all cell types in a brain region, irrespective of their individual transcriptomic/molecular identities, while only a subset of cells in a region project to VTA<sup>DA</sup> cells. Nonetheless, our CRISPRi experiment showing that a mild reduction of <italic>Cacna1e</italic> reduces RABV labeling indicates the potential for causative associations between gene expression patterns and drug-induced RABV input labeling changes (<xref rid="fig10" ref-type="fig">Figure 10</xref>). This result also directly links cellular excitability and the extent to which RABV labels these cells as monosynaptic inputs to defined cell populations. While our experiments do not prove that any particular gene expression changes drive changes in RABV labeling, they provide a nice starting point for follow-up experiments.</p>
<p>Our RABV screen identified several input sites that show elevated or depressed labeling following a single administration of an addictive drug, suggesting potential changes in excitability of these cells. Ca<sup>2+</sup> channel genes were also highly negatively correlated with the extent of drug-induced changes in RABV input labeling. Ca<sup>2+</sup> channels have been implicated in substance misuse through Genome-Wide Association Studies<sup><xref ref-type="bibr" rid="c81">81</xref></sup>, and molecules that target these channels have shown some promise as addiction therapeutics<sup><xref ref-type="bibr" rid="c82">82</xref>–<xref ref-type="bibr" rid="c87">87</xref></sup>. It is of particular interest that Ca<sup>2+</sup> and not Cl<sup>-</sup>, Na<sup>+</sup>, or K<sup>+</sup> channels are highly correlated to RABV input labeling changes. Ca<sup>2+</sup> is critically involved as a secondary messenger in neurons that affects a variety of processes including long- lasting changes in transcription and synaptic transmission, whereas the other ions are mostly involved only in facilitating or inhibiting formation and propagation of the action potential. Understanding how Ca<sup>2+</sup> channel gene expression levels relate to drug-induced changes in the brain will help to illuminate the relationship between basal gene expression levels, drug-induced changes in RABV labeling, and substance misuse, providing mechanistic insights into how inter- individual differences influence susceptibility to substance misuse.</p>
</sec>
</sec>
</body>
<back>
<sec sec-type="supplementary" id="supplementary33">
<fig id="figs1" position="float" orientation="portrait" fig-type="figure">
<label>Figure S1:</label>
<caption><title>Representative images showing anatomical boundaries for the 22 defined input regions.</title>
<p>Each input region is denoted where it is present, and each region is denoted on at least one section.</p></caption>
<graphic xlink:href="520804v3_figs1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs2" position="float" orientation="portrait" fig-type="figure">
<label>Figure S2:</label>
<caption><title>Example images of starter cell distribution from mice in different treatment groups.</title>
<p>Red reflects expression of TVA-mCherry; green reflects expression of GFP from RABV; yellow reflects overlap. Related to <xref rid="fig4" ref-type="fig">Figure 4A</xref>.</p></caption>
<graphic xlink:href="520804v3_figs2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs3" position="float" orientation="portrait" fig-type="figure">
<label>Figure S3:</label>
<caption>
<title>Brains from animals treated with a single exposure to a drug (<xref rid="fig5" ref-type="fig">Figure 5A</xref>), but with the brain identities scrambled.</title>
<p>(A) PCA plot showing the data with scrambled identities along PC1 and PC2. (B) The same scrambled data along PC1 and PC3. (C) UMAP of the scrambled data. (D) Correlogram of 20 UMAP embeddings of the scrambled data.</p>
</caption>
<graphic xlink:href="520804v3_figs3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs4" position="float" orientation="portrait" fig-type="figure">
<label>Figure S4:</label>
<caption>
<title>Dimensionality reduction analysis of brains from animals anesthetized with isoflurane and treated with either cocaine or saline, or anesthetized with ketamine/xylazine and treated with saline, focusing on PC3.</title>
<p>(A) PCA plot of input data from VTA<sup>DA</sup> cells from mice anesthetized either with isoflurane or K/X and given saline, showing PC2 and PC3. (B) Box plot comparisons of PC3, p = 0.99, unpaired t-tests, n = 4 for both. (C) PCA plot of RABV input mapping experiments to VTA<sup>DA</sup>→NAcLat cells in mice anesthetized with isoflurane and given saline or cocaine, or anesthetized with K/X and given saline, showing PC2 and PC3. (D) Box plot comparisons of PC3, One-way ANOVA p = 0.12. n=4 for saline and K/X, n = 5 for cocaine. (E) PCA plot of input mapping experiments to VTA<sup>DA</sup>→Amygdala cells, showing PC2 and PC3. (F) Box plot comparisons of PC3, PC1, One-way ANOVA p = 0.014, pairwise t-tests saline vs. K/X multiple comparisons adjusted p = 0.011, saline vs. cocaine p = 0.24, K/X vs. cocaine p = 0.16. n = 4 for saline, n = 5 for K/X and cocaine. (G) PCA plot of input mapping experiments to VTA<sup>DA</sup>→NAcMed cells, showing PC2 and PC3. (H) Box plot comparisons of PC3,, One-way ANOVA p = 0.64. PC2, One-way ANOVA p = 0.16, n = 4 for saline and K/X, n = 5 for cocaine. (I) PCA plot of input mapping experiments to VTA<sup>DA</sup>→mPFC cells, showing PC2 and PC3. (J) Box plot comparisons of PC3, One-way ANOVA p = 0.67. PC2, One-way ANOVA p = 0.083. n = 4 for saline and cocaine, n = 5 for K/X.</p>
</caption>
<graphic xlink:href="520804v3_figs4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs5" position="float" orientation="portrait" fig-type="figure">
<label>Figure S5:</label>
<caption>
<title>Additional cTRIO data from mice anesthetized with K/X and given saline or isoflurane and given saline or cocaine.</title>
<p>(A) PCA plot of input mapping experiments to VTA<sup>DA</sup>→NAcMed cells. Box plot comparisons of PC1 and PC2 are shown to the right. PC1, One-way ANOVA p = 0.64. PC2, One-way ANOVA p = 0.27. n=4 for saline and K/X, n = 5 for cocaine. (B) Bar plot showing percent of RABV-labeled cells in each input region for cTRIO experiments from VTA<sup>DA</sup>→NAcMed cells. (C) Heatmap of the contributions of each brain region to PC1 to PC3 for data shown in panel A. (D) UMAP plot of input mapping experiments to VTA<sup>DA</sup>→NAcMed cells. (E) PCA plot of input mapping experiments to VTA<sup>DA</sup>→mPFC cells. Box plot comparisons of PC1 and PC2 are shown to the right. PC1, One-way ANOVA p = 0.67. PC2, One-way ANOVA p = 0.97. n=4 for saline and cocaine, n = 5 for K/X. (F) Bar plot showing percent of RABV-labeled cells in each input region for cTRIO experiments from VTA<sup>DA</sup>→mPFC cells. (G) Heatmap of the contributions of each brain region to PC1 to PC3 for data shown in panel E. (H) UMAP plot of input mapping experiments to VTA<sup>DA</sup>→mPFC cells.</p>
</caption>
<graphic xlink:href="520804v3_figs5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs6" position="float" orientation="portrait" fig-type="figure">
<label>Figure S6:</label>
<caption>
<title>Inputs to brains of mice anesthetized with isoflurane and receiving saline or cocaine, or K/X-saline (<xref rid="fig7" ref-type="fig">Figure 7</xref>), but with the brain identities scrambled.</title>
<p>(A) PCA plot of scrambled data from all VTA<sup>DA</sup> cells including isoflurane-anesthetized and K/X- anesthetized mice. (B) UMAP plot of scrambled data from all VTA<sup>DA</sup> cells including isoflurane-anesthetized and K/X- anesthetized mice. (C) PCA plot of scrambled data from input mapping experiments to VTA<sup>DA</sup>→NAcLat cells. (D) UMAP plot of scrambled data from input mapping experiments to VTA<sup>DA</sup>→NAcLat cells. (E) PCA plot of scrambled data from input mapping experiments to VTA<sup>DA</sup>→Amygdala cells. (F) UMAP plot of scrambled data from input mapping experiments to VTA<sup>DA</sup>→Amygdala cells. (G) PCA plot of scrambled data from input mapping experiments to VTA<sup>DA</sup>→NAcMed cells. (H) UMAP plot of scrambled data from input mapping experiments to VTA<sup>DA</sup>→NAcMed cells. (I) PCA plot of scrambled data from input mapping experiments to VTA<sup>DA</sup>→mPFC cells. (J) UMAP plot of scrambled data from input mapping experiments to VTA<sup>DA</sup>→mPFC cells.</p>
</caption>
<graphic xlink:href="520804v3_figs6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs7" position="float" orientation="portrait" fig-type="figure">
<label>Figure S7:</label>
<caption><title>Gene ontology analysis of top 50 expressed genes correlated to differences in RABV input labeling obtained from drug-treated vs. control mice.</title>
<p>GO from mice treated with (A) amphetamine, (B) cocaine, (C) methamphetamine, (D) morphine, and (E) nicotine-treated relative to saline-injected controls are shown. Each GO analysis reflects molecular function- related gene classes whose expression was negatively correlated with RABV labeling differences.</p></caption>
<graphic xlink:href="520804v3_figs7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs8" position="float" orientation="portrait" fig-type="figure">
<label>Figure S8:</label>
<caption><title>Gene ontology analysis of top 50 expressed genes correlated to differences in RABV input labeling obtained from drug-treated vs. control mice.</title><p>GO analyses from mice treated with (A) amphetamine, (B) cocaine, (C) methamphetamine, (D) morphine, and (E) nicotine-treated relative to saline-injected controls are shown. Each GO analysis reflects biological process-related gene classes whose expression was positively correlated with RABV labeling differences.</p></caption>
<graphic xlink:href="520804v3_figs8.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs9" position="float" orientation="portrait" fig-type="figure">
<label>Figure S9:</label>
<caption><title>Gene ontology analysis of the top 50 genes correlated with differences in RABV input labeling obtained from fluoxetine vs. saline-treated controls.</title>
<p>Panel (A) shows molecular function-related gene classes whose expression was positively correlated with RABV labeling differences, and panel (B) shows GO analyses that reflect biological process-related gene classes whose expression was negatively correlated with RABV labeling differences.</p></caption>
<graphic xlink:href="520804v3_figs9.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs10" position="float" orientation="portrait" fig-type="figure">
<label>Figure S10:</label>
<caption><title>Relationship between RABV labeling ratio in addictive drug/saline-treated groups and mean basal gene expression of gene subgroups.</title>
<p>Linear regressions are shown for all five examined drugs against all genes and different gene classes expressed by brain region within the Allen Gene Expression Atlas, including (A) all genes, (B) substance dependence- related genes, (C) endocytosis- and exocytosis-related genes, (D) mitochondrial genes, (E) sugar transporter genes, (F) tumor-associated genes, (G) ligand-gated ion channel genes, (H) voltage- gated ion channel genes, (I) other ion channel genes.</p></caption>
<graphic xlink:href="520804v3_figs10.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs11" position="float" orientation="portrait" fig-type="figure">
<label>Figure S11:</label>
<caption><title>Relationship between RABV labeling ratio in K/X-saline vs. isoflurane-saline groups and mean basal gene expression of gene subgroups.</title>
<p>Linear regressions are shown for K/X-saline vs. isoflurane-saline groups against different gene classes, including (A) ion channel-related genes, (B) synapse-related genes, (C) neurotransmitter-related genes, (D) DEGs related to substance misuse, (E) voltage-gated ion channels, (F) ligand-gated ion channels, (G) other ion channels, (H) K<sup>+</sup> channels, (I) Ca<sup>2+</sup> channels, (J) Cl<sup>-</sup> channels, (K) Na<sup>+</sup> channels, (L) glutamate receptors, (M) glycine receptors, (N) acetylcholine receptors, (O) GABA receptor genes.</p></caption>
<graphic xlink:href="520804v3_figs11.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs12" position="float" orientation="portrait" fig-type="figure">
<label>Figure S12:</label>
<caption><title>Relationship between RABV ratio labeling in fluoxetine vs. saline-treated groups, both anesthetized with isoflurane, and mean basal gene expression of gene subgroups.</title>
<p>Linear regressions are shown for fluoxetine/saline-treated groups against different gene classes, including (A) ion channel-related genes, (B) synapse-related genes, (C) neurotransmitter-related genes, (D) DEGs related to substance misuse, (E) voltage-gated ion channels, (F) ligand-gated ion channels, (G) other ion channels, (H) K<sup>+</sup> channels, (I) Ca<sup>2+</sup> channels, (J) Cl<sup>-</sup> channels, (K) Na<sup>+</sup> channels, (L) glutamate receptors, (M) glycine receptors, (N) acetylcholine receptors, (O) GABA receptor genes.</p></caption>
<graphic xlink:href="520804v3_figs12.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs13" position="float" orientation="portrait" fig-type="figure">
<label>Figure S13:</label>
    <caption><title>Atlas and AGEA data showing expression of <italic>Cacna1e</italic>.</title>
        <p>Shown are both coronal (<bold>A-C</bold>) and parasagittal (<bold>D-F</bold>) sections. The NAc is highlighted in panels B and E. The colors in panels C and F reflect the expression energy of <italic>Cacna1e</italic>; the color bar is shown to the right of panel F. Expression of <italic>Cacna1e</italic> is relatively uniform and high throughout the striatum, including the NAc. Imags are from the Allen Mouse Brain Reference Atlas, and <italic>in situ</italic> hybridization/AGEA data from</p></caption>
<graphic xlink:href="520804v3_figs13.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="das" sec-type="data-availability">
<title>Data availability</title>
    <p>The current manuscript is largely computational study, so no data have been generated for most of this manuscript, except for <xref ref-type="fig" rid="fig10">Figure 10</xref>; raw data are available for <xref ref-type="fig" rid="fig10">Figure 10</xref> upon reasonable request.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>We would like to thank Hemmings Wu and Zhoule Zhu for their thoughtful critique of our manuscript.</p>
</ack>
<sec id="additional-info" sec-type="additional-information">
<title>Additional information</title>
<sec id="s5">
<title>Author contributions</title>
<p>KTB performed the majority of experiments, KB assisted with performing computational analyses of the data, PD assisted with network constructions and projection portraits, MH assisted with figure preparation, GT, JJV, and GA performed CRISPRi experiments, and KTB wrote the manuscript.</p>
</sec>
<sec id="s6">
<title>Funding</title>
<p>This work was supported by the NIH (R00 DA041445, DP2 AG067666, R01 DA054374, R01 DA056599, R01 NS130044), Tobacco Related Disease Research Program (T31KT1437, T31P1426), American Parkinson Disease Association (APDA-5589562), Alzheimer’s Association (AARG-NTF-20-685694), New Vision Research (CCAD2020-002), Brightfocus Foundation (A2022031S), and the Brain and Behavior Research Foundation (NARSAD 26845) to KTB, NIH T3 2GM008620 and NIH F30 DA056215 to MH, T32 GM136624 to KB and PD, and NSF GRFP DGE-1839285 to PD.</p>
</sec>
<sec id="s7">
<title>Code availability</title>
<p>Code used for this work is available on GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/ktbartas/Bartas_et_al_eLife_2024">https://github.com/ktbartas/Bartas_et_al_eLife_2024</ext-link>).</p>
</sec>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bromberg-Martin</surname>, <given-names>E. S.</given-names></string-name>, <string-name><surname>Matsumoto</surname>, <given-names>M.</given-names></string-name> &amp; <string-name><surname>Hikosaka</surname>, <given-names>O</given-names></string-name></person-group>. <article-title>Dopamine in Motivational Control: Rewarding, Aversive, and Alerting</article-title>. <source>Neuron</source> <volume>68</volume>, <fpage>815</fpage>–<lpage>834</lpage> (<year>2010</year>).</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lammel</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Lim</surname>, <given-names>B. K.</given-names></string-name> &amp; <string-name><surname>Malenka</surname>, <given-names>R. C</given-names></string-name></person-group>. <article-title>Reward and aversion in a heterogeneous midbrain dopamine system</article-title>. <source>Neuropharmacology</source> <volume>76</volume>, <fpage>351</fpage>–<lpage>359</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wise</surname>, <given-names>R. A.</given-names></string-name></person-group>, <article-title>Dopamine, learning and motivation</article-title>. <source>Nat Rev Neurosci</source> <volume>5</volume>, <fpage>483</fpage>–<lpage>494</lpage> (<year>2004</year>).</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>, <given-names>C. K.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Simultaneous fast measurement of circuit dynamics at multiple sites across the mammalian brain</article-title>. <source>Nat Methods</source> <volume>13</volume>, <fpage>325</fpage>–<lpage>8</lpage> (<year>2016</year>).</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lammel</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Ion</surname>, <given-names>D. I.</given-names></string-name>, <string-name><surname>Roeper</surname>, <given-names>J.</given-names></string-name> &amp; <string-name><surname>Malenka</surname>, <given-names>R. C</given-names></string-name></person-group>. <article-title>Report Projection-Specific Modulation of Dopamine Neuron Synapses by Aversive and Rewarding Stimuli</article-title>. <source>Neuron</source> <volume>70</volume>, <fpage>855</fpage>–<lpage>862</lpage> (<year>2011</year>).</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lammel</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Input-specific control of reward and aversion in the ventral tegmental area</article-title>. <source>Nature</source> <volume>491</volume>, <fpage>212</fpage>–<lpage>217</lpage> (<year>2012</year>).</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beier</surname>, <given-names>K. T.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Circuit Architecture of VTA Dopamine Neurons Revealed by Systematic Input-Output Mapping</article-title>. <source>Cell</source> <volume>162</volume>, <fpage>622</fpage>–<lpage>634</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Menegas</surname>, <given-names>W.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Dopamine neurons projecting to the posterior striatum form an anatomically distinct subclass</article-title>. <source>eLife</source> <volume>4</volume>, <fpage>1</fpage>–<lpage>30</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Watabe-Uchida</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Zhu</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Ogawa</surname>, <given-names>S. K.</given-names></string-name>, <string-name><surname>Vamanrao</surname>, <given-names>A.</given-names></string-name> &amp; <string-name><surname>Uchida</surname>, <given-names>N</given-names></string-name></person-group>. <article-title>Whole-Brain Mapping of Direct Inputs to Midbrain Dopamine Neurons</article-title>. <source>Neuron</source> <volume>74</volume>, <fpage>858</fpage>–<lpage>873</lpage> (<year>2012</year>).</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beier</surname>, <given-names>K. T.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Topological Organization of Ventral Tegmental Area Connectivity Revealed by Viral-Genetic Dissection of Input-Output Relations</article-title>. <source>Cell Rep</source> <volume>26</volume>, <fpage>159</fpage>–<lpage>167.e6</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cardozo Pinto</surname>, <given-names>D. F.</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Characterization of transgenic mouse models targeting neuromodulatory systems reveals organizational principles of the dorsal raphe</article-title>. <source>Nat Commun</source> <volume>10</volume>, (<year>2019</year>).</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Faget</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Afferent Inputs to Neurotransmitter-Defined Cell Types in the Ventral Tegmental Area</article-title>. <source>Cell Rep</source> <volume>15</volume>, <fpage>2796</fpage>–<lpage>2808</lpage> (<year>2016</year>).</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kalivas</surname>, <given-names>P. W.</given-names></string-name> &amp; <string-name><surname>Volkow</surname>, <given-names>N. D</given-names></string-name></person-group>. <article-title>The neural basis of addiction: a pathology of motivation and choice</article-title>. <source>Am J Psychiatry</source> <volume>162</volume>, <fpage>1403</fpage>–<lpage>1413</lpage> (<year>2005</year>).</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hyman</surname>, <given-names>S. E.</given-names></string-name>, <string-name><surname>Malenka</surname>, <given-names>R. C.</given-names></string-name> &amp; <string-name><surname>Nestler</surname>, <given-names>E. J</given-names></string-name></person-group>. <article-title>Neural mechanisms of addiction: the role of reward-related learning and memory</article-title>. <source>Annu Rev Neurosci</source> <volume>29</volume>, <fpage>565</fpage>–<lpage>598</lpage> (<year>2006</year>).</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beier</surname>, <given-names>K. T.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Rabies screen reveals GPe control of cocaine-triggered plasticity</article-title>. <source>Nature</source> <volume>549</volume>, <fpage>345</fpage>–<lpage>350</lpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tian</surname>, <given-names>G.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>An extended Amygdal-midbrain circuit controlling cocaine withdrawal- induced anxiety and reinstatement</article-title>. <source>Cell Rep</source> <volume>39</volume>, <fpage>1</fpage>–<lpage>16</lpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Juarez</surname>, <given-names>B.</given-names></string-name> &amp; <string-name><surname>Han</surname>, <given-names>M. H</given-names></string-name></person-group>. <article-title>Diversity of Dopaminergic Neural Circuits in Response to Drug Exposure</article-title>. <source>Neuropsychopharmacology</source> <volume>41</volume>, <fpage>2424</fpage>–<lpage>2446</lpage> (<year>2016</year>).</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mahler</surname>, <given-names>S. V</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Chemogenetic Manipulations of Ventral Tegmental Area Dopamine Neurons Reveal Multifaceted Roles in Cocaine Abuse</article-title>. <source>Journal of Neuroscience</source> <volume>39</volume>, <fpage>503</fpage>– <lpage>518</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saal</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Dong</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Bonci</surname>, <given-names>A.</given-names></string-name> &amp; <string-name><surname>Malenka</surname>, <given-names>R. C</given-names></string-name></person-group>. <article-title>Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons</article-title>. <source>Neuron</source> <volume>37</volume>, <fpage>577</fpage>–<lpage>582</lpage> (<year>2003</year>).</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ungless</surname>, <given-names>M. A.</given-names></string-name>, <string-name><surname>Whistler</surname>, <given-names>J. L.</given-names></string-name>, <string-name><surname>Malenka</surname>, <given-names>R. C.</given-names></string-name> &amp; <string-name><surname>Bonci</surname>, <given-names>A</given-names></string-name></person-group>. <article-title>Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons</article-title>. <source>Nature</source> <volume>411</volume>, <fpage>583</fpage>–<lpage>7</lpage>. (<year>2001</year>).</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Niehaus</surname>, <given-names>J. L.</given-names></string-name>, <string-name><surname>Murali</surname>, <given-names>M.</given-names></string-name> &amp; <string-name><surname>Kauer</surname>, <given-names>J. A</given-names></string-name></person-group>. <article-title>Drugs of abuse and stress impair LTP at inhibitory synapses in the ventral tegmental area</article-title>. <source>European Journal of Neuroscience</source> <volume>32</volume>, <fpage>108</fpage>–<lpage>117</lpage> (<year>2010</year>).</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bocklisch</surname>, <given-names>C.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Cocaine Disinhibits Dopamine Neurons by Potentiation of GABA Transmission in the Ventral Tegmental Area</article-title>. <source>Science</source> <volume>341</volume>, <fpage>1521</fpage>–<lpage>1525</lpage> (<year>2013</year>).</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dong</surname>, <given-names>Y.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Cocaine-induced potentiation of synaptic strength in dopamine neurons: behavioral correlates in GluRA(-/-) mice</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>101</volume>, <fpage>14282</fpage>–<lpage>14287</lpage> (<year>2004</year>).</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Creed</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Cocaine exposure enhances the activity of ventral tegmental area dopamine neurons via calcium-impermeable NMDARs</article-title>. <source>Journal of Neuroscience</source> <volume>36</volume>, <fpage>10759</fpage>–<lpage>10768</lpage> (<year>2016</year>).</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tian</surname>, <given-names>G.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>An extended Amygdala-midbrain circuit controlling cocaine withdrawal- induced anxiety and reinstatement</article-title>. <source>Cell Rep</source> <volume>39</volume>, <fpage>1</fpage>–<lpage>16</lpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Backman</surname>, <given-names>C. M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Characterization of a mouse strain expressing Cre recombinase from the 3’ untranslated region of the dopamine transporter locus</article-title>. <source>Genesis</source> <volume>44</volume>, <fpage>383</fpage>–<lpage>390</lpage> (<year>2006</year>).</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Taniguchi</surname>, <given-names>H.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>A Resource of Cre Driver Lines for Genetic Targeting of GABAergic Neurons in Cerebral Cortex</article-title>. <source>Neuron</source> <volume>71</volume>, <fpage>995</fpage>–<lpage>1013</lpage> (<year>2011</year>).</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vong</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Leptin Action on GABAergic Neurons Prevents Obesity and Reduces Inhibitory Tone to POMC Neurons</article-title>. <source>Neuron</source> <volume>71</volume>, <fpage>142</fpage>–<lpage>154</lpage> (<year>2011</year>).</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumar</surname>, <given-names>N.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>The development of an AAV-based crispr sacas9 genome editing system that can be delivered to neurons in vivo and regulated via doxycycline and cre- recombinase</article-title>. <source>Front Mol Neurosci</source> <volume>11</volume>, <fpage>1</fpage>–<lpage>14</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pedregosa</surname>, <given-names>F.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Scikit-learn: Machine Learning in Python</article-title>. <source>Journal of Machine Learning Research</source> <volume>12</volume>, <fpage>2825</fpage>–<lpage>2830</lpage> (<year>2011</year>).</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="preprint"><person-group person-group-type="author"><string-name><surname>McInnes</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Healy</surname>, <given-names>J.</given-names></string-name> &amp; <string-name><surname>Melville</surname>, <given-names>J</given-names></string-name></person-group>. <article-title>UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction</article-title>. <source>ArXiv</source> (<year>2018</year>).</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Derdeyn</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Hui</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Macchia</surname>, <given-names>D.</given-names></string-name> &amp; <string-name><surname>Beier</surname>, <given-names>K</given-names></string-name></person-group>. <article-title>Uncovering the Connectivity Logic of the Ventral Tegmental Area</article-title>. <source>Front Neural Circuits</source> <volume>15</volume>, <fpage>799688</fpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Waskom</surname>, <given-names>M</given-names></string-name></person-group>. <article-title>Seaborn: Statistical Data Visualization</article-title>. <source>J Open Source Softw</source> <volume>6</volume>, <fpage>3021</fpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hunter</surname>, <given-names>J. D</given-names></string-name></person-group>. <article-title>Matplotlib: a 2D graphics environment</article-title>. <source>Comput Sci Eng</source> <volume>9</volume>, <fpage>90</fpage>–<lpage>95</lpage> (<year>2007</year>).</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chon</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>Vanselow</surname>, <given-names>D. J.</given-names></string-name>, <string-name><surname>Cheng</surname>, <given-names>K. C.</given-names></string-name> &amp; <string-name><surname>Kim</surname>, <given-names>Y</given-names></string-name></person-group>. <article-title>Enhanced and unified anatomical labeling for a common mouse brain atlas</article-title>. <source>Nat Commun</source> <volume>10</volume>, (<year>2019</year>).</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Oh</surname>, <given-names>S. W.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>A mesoscale connectome of the mouse brain</article-title>. <source>Nature</source> <volume>508</volume>, <fpage>207</fpage>–<lpage>214</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lein</surname>, <given-names>E. S.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Genome-wide atlas of gene expression in the adult mouse brain</article-title>. <source>Nature</source> <volume>445</volume>, <fpage>168</fpage>–<lpage>176</lpage> (<year>2007</year>).</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brynildsen</surname>, <given-names>J. K.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Gene coexpression patterns predict opiate-induced brain-state transitions</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>117</volume>, <fpage>19556</fpage>–<lpage>19565</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fulcher</surname>, <given-names>B. D.</given-names></string-name>, <string-name><surname>Murray</surname>, <given-names>J. D.</given-names></string-name>, <string-name><surname>Zerbi</surname>, <given-names>V.</given-names></string-name> &amp; <string-name><surname>Wang</surname>, <given-names>X. J</given-names></string-name></person-group>. <article-title>Multimodal gradients across mouse cortex</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>116</volume>, <fpage>4689</fpage>–<lpage>4695</lpage> (<year>2019</year>).</mixed-citation></ref>
    <ref id="c40"><label>40.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Sian</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Youdim</surname>, <given-names>M.</given-names></string-name> &amp; <string-name><surname>Riederer</surname>, <given-names>P</given-names></string-name>, <etal>et al.</etal></person-group> <chapter-title>Biochemical Anatomy of the Basal Ganglia and Associated Neural Systems</chapter-title>. in <source>Basic Neurochemistry: Molecular, Cellular and Medical Aspects</source>. <person-group person-group-type="editor"><string-name><surname>Siegel</surname> <given-names>G</given-names></string-name>, <string-name><surname>Agranoff</surname> <given-names>B</given-names></string-name>, <string-name><surname>Albers</surname> <given-names>RW</given-names></string-name> <etal>et al</etal></person-group> (<year>1999</year>).</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xie</surname>, <given-names>Z.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Gene Set Knowledge Discovery with Enrichr</article-title>. <source>Curr Protoc</source> <volume>1</volume>, <fpage>1</fpage>–<lpage>51</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ji</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>H.</given-names></string-name> &amp; <string-name><surname>Cui</surname>, <given-names>Q</given-names></string-name></person-group>. <article-title>A Panel of Synapse-Related Genes as a Biomarker for Gliomas</article-title>. <source>Front Neurosci</source> <volume>14</volume>, <fpage>1</fpage>–<lpage>8</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>, <given-names>R.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Ion channel gene expression predicts survival in glioma patients</article-title>. <source>Sci Rep</source> <volume>5</volume>, <fpage>1</fpage>–<lpage>10</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Berchtold</surname>, <given-names>N. C.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer’s disease</article-title>. <source>Neurobiol Aging</source> <volume>34</volume>, <fpage>1653</fpage>–<lpage>1661</lpage> (<year>2013</year>).</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shi</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>AddictGene: An integrated knowledge base for differentially expressed genes associated with addictive substance</article-title>. <source>Comput Struct Biotechnol J</source> <volume>19</volume>, <fpage>2416</fpage>–<lpage>2422</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saheki</surname>, <given-names>Y.</given-names></string-name> &amp; <string-name><surname>De Camilli</surname>, <given-names>P.</given-names></string-name></person-group> <article-title>Synaptic vesicle endocytosis</article-title>. <source>Cold Spring Harb Perspect Biol</source> <volume>4</volume>, (<year>2012</year>).</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harding</surname>, <given-names>S. D.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>The IUPHAR/BPS guide to PHARMACOLOGY in 2022: Curating pharmacology for COVID-19, malaria and antibacterials</article-title>. <source>Nucleic Acids Res</source> <volume>50</volume>, <fpage>D1282</fpage>– <lpage>D1294</lpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yamaguchi</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>H. L.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Ng</surname>, <given-names>T. H.</given-names></string-name> &amp; <string-name><surname>Morales</surname>, <given-names>M</given-names></string-name></person-group>. <article-title>Mesocorticolimbic glutamatergic pathway</article-title>. <source>Journal of Neuroscience</source> <volume>31</volume>, <fpage>8476</fpage>–<lpage>8490</lpage> (<year>2011</year>).</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yamaguchi</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Sheen</surname>, <given-names>W.</given-names></string-name> &amp; <string-name><surname>Morales</surname>, <given-names>M</given-names></string-name></person-group>. <article-title>Glutamatergic neurons are present in the rat ventral tegmental area</article-title>. <source>European Journal of Neuroscience</source> <volume>25</volume>, <fpage>106</fpage>–<lpage>118</lpage> (<year>2007</year>).</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Root</surname>, <given-names>D. H.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Single rodent mesohabenular axons release glutamate and GABA</article-title>. <source>Nat Neurosci</source> <volume>17</volume>, <fpage>1543</fpage>–<lpage>1551</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morales</surname>, <given-names>M.</given-names></string-name> &amp; <string-name><surname>Margolis</surname>, <given-names>E. B</given-names></string-name></person-group>. <article-title>Ventral tegmental area: Cellular heterogeneity, connectivity and behaviour</article-title>. <source>Nat Rev Neurosci</source> <volume>18</volume>, <fpage>73</fpage>–<lpage>85</lpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hnasko</surname>, <given-names>T. S.</given-names></string-name>, <string-name><surname>Hjelmstad</surname>, <given-names>G. O.</given-names></string-name>, <string-name><surname>Fields</surname>, <given-names>H. L.</given-names></string-name> &amp; <string-name><surname>Edwards</surname>, <given-names>R. H</given-names></string-name></person-group>. <article-title>Ventral tegmental area glutamate neurons: electrophysiological properties and projections</article-title>. <source>Journal of Neuroscience</source> <volume>32</volume>, <fpage>15076</fpage>–<lpage>15085</lpage> (<year>2012</year>).</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>, <given-names>J. I.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Aldehyde dehydrogenase 1a1 mediates a GABA synthesis pathway in midbrain dopaminergic neurons</article-title>. <source>Science</source> <volume>350</volume>, <fpage>102</fpage>–<lpage>106</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tritsch</surname>, <given-names>N. X.</given-names></string-name>, <string-name><surname>Ding</surname>, <given-names>J. B.</given-names></string-name> &amp; <string-name><surname>Sabatini</surname>, <given-names>B. L</given-names></string-name></person-group>. <article-title>Dopaminergic neurons inhibit striatal output through non-canonical release of GABA</article-title>. <source>Nature</source> <volume>490</volume>, <fpage>262</fpage>–<lpage>266</lpage> (<year>2012</year>).</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koob</surname>, <given-names>G. F</given-names></string-name></person-group>. <article-title>A Role for Brain Stress Systems in Addiction</article-title>. <source>Neuron</source> <volume>59</volume>, <fpage>11</fpage>–<lpage>34</lpage> (<year>2008</year>).</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koob</surname>, <given-names>G. F</given-names></string-name></person-group>. <article-title>Brain stress systems in the amygdala and addiction</article-title>. <source>Brain Res</source> <volume>1293</volume>, <fpage>61</fpage>–<lpage>75</lpage> (<year>2009</year>).</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tian</surname>, <given-names>G.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Molecular and circuit determinants in the globus pallidus mediating control of cocaine-induced behavioral plasticity</article-title>. <source>Neuron</source> <volume>112</volume>, <fpage>3470</fpage>–<lpage>3485.e12</lpage> (<year>2024</year>).</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lammel</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Unique Properties of Mesoprefrontal Neurons within a Dual Mesocorticolimbic Dopamine System</article-title>. <source>Neuron</source> <volume>57</volume>, <fpage>760</fpage>–<lpage>773</lpage> (<year>2008</year>).</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Larson</surname>, <given-names>M. H.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>CRISPR interference (CRISPRi) for sequence-specific control of gene expression</article-title>. <source>Nat Protoc</source> <volume>8</volume>, <fpage>2180</fpage>–<lpage>2196</lpage> (<year>2013</year>).</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>, <given-names>H.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Entopeduncular nucleus projections to the lateral habenula contribute to cocaine avoidance</article-title>. <source>Journal of Neuroscience</source> <volume>41</volume>, <fpage>298</fpage>–<lpage>306</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>López</surname>, <given-names>A. J.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Medial habenula cholinergic signaling regulates cocaine-associated relapse-like behavior</article-title>. <source>Addiction Biology</source> <volume>24</volume>, <fpage>403</fpage>–<lpage>413</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tan</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Nuno-Perez</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Mameli</surname>, <given-names>M.</given-names></string-name> &amp; <string-name><surname>Meye</surname>, <given-names>F. J</given-names></string-name></person-group>. <article-title>Cocaine withdrawal reduces GABABR transmission at entopeduncular nucleus – lateral habenula synapses</article-title>. <source>European Journal of Neuroscience</source> <volume>50</volume>, <fpage>2124</fpage>–<lpage>2133</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koob</surname>, <given-names>G. F.</given-names></string-name> &amp; <string-name><surname>Volkow</surname>, <given-names>N. D.</given-names></string-name></person-group> <article-title>Neurocircuitry of addiction</article-title>. <source>Neuropsychopharmacology</source> <volume>35</volume>, <fpage>217</fpage>–<lpage>238</lpage> (<year>2010</year>).</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marchant</surname>, <given-names>N. J.</given-names></string-name>, <string-name><surname>Zayra Millan</surname>, <given-names>E.</given-names></string-name> &amp; <string-name><surname>McNally</surname>, <given-names>G. P</given-names></string-name></person-group>. <article-title>The hypothalamus and the neurobiology of drug seeking</article-title>. <source>Cellular and Molecular Life Sciences</source> vol. <volume>69</volume> <fpage>581</fpage>–<lpage>597</lpage> Preprint at <pub-id pub-id-type="doi">10.1007/s00018-011-0817-0</pub-id> (<year>2012</year>).</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sheng</surname>, <given-names>H.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Nucleus accumbens circuit disinhibits lateral hypothalamus glutamatergic neurons contributing to morphine withdrawal memory in male mice</article-title>. <source>Nat Commun</source> <volume>14</volume>, (<year>2023</year>).</mixed-citation></ref>
    <ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DiLeone</surname>, <given-names>R. J.</given-names></string-name>, <string-name><surname>Georgescu</surname>, <given-names>D.</given-names></string-name> &amp; <string-name><surname>Nestler</surname>, <given-names>E. J</given-names></string-name></person-group>. <article-title>Lateral hypothalamic neuropeptides in reward and drug addiction</article-title>. in <source>Life Sciences</source> vol. <volume>73</volume> <fpage>759</fpage>–<lpage>768</lpage> (<year>2003</year>).</mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aston-Jones</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Smith</surname>, <given-names>R. J.</given-names></string-name>, <string-name><surname>Moorman</surname>, <given-names>D. E.</given-names></string-name> &amp; <string-name><surname>Richardson</surname>, <given-names>K. A.</given-names></string-name> .  vol.  – <collab>Preprint at</collab></person-group><article-title>Role of lateral hypothalamic orexin neurons in reward processing and addiction</article-title>. <source>Neuropharmacology</source> vol. <volume>56</volume> <fpage>112</fpage>–<lpage>121</lpage>  <pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.06.060</pub-id> (<year>2009</year>).</mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>He</surname>, <given-names>T.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>A novel cholinergic projection from the lateral parabrachial nucleus and its role in methamphetamine-primed conditioned place preference</article-title>. <source>Brain Commun</source> <volume>4</volume>, (<year>2022</year>).</mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pyeon</surname>, <given-names>G. H.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>J. H.</given-names></string-name>, <string-name><surname>Choi</surname>, <given-names>J. S.</given-names></string-name> &amp; <string-name><surname>Jo</surname>, <given-names>Y. S</given-names></string-name></person-group>. <article-title>Activation of CGRP neurons in the parabrachial nucleus suppresses addictive behavior</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>121</volume>, (<year>2024</year>).</mixed-citation></ref>
    <ref id="c70"><label>70.</label><mixed-citation publication-type="preprint"><person-group person-group-type="author"><string-name><surname>Tian</surname> <given-names>G</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Molecular and circuit determinants in the globus pallidus mediating control of cocaine-induced behavioral plasticity</article-title>. <source>SSRN</source> <pub-id pub-id-type="doi">10.2139/ssrn.4549829</pub-id> (<year>2023</year>).</mixed-citation></ref>
<ref id="c71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Lin</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>B.</given-names></string-name> &amp; <string-name><surname>Zhou</surname>, <given-names>W</given-names></string-name></person-group>. <article-title>Ketamine abuse potential and use disorder</article-title>. <source>Brain Res Bull</source> <volume>126</volume>, <fpage>68</fpage>–<lpage>73</lpage> (<year>2016</year>).</mixed-citation></ref>
<ref id="c72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ni</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Lee Cantrell</surname>, <given-names>F.</given-names></string-name> &amp; <string-name><surname>Clark</surname>, <given-names>R. F</given-names></string-name></person-group>. <article-title>Ketamine exposure demographics and outcomes over 16 years as reported to US poison centers</article-title>. <source>American Journal of Emergency Medicine</source> <volume>36</volume>, <fpage>1459</fpage>–<lpage>1462</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dillon</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Copeland</surname>, <given-names>J.</given-names></string-name> &amp; <string-name><surname>Jansen</surname>, <given-names>K</given-names></string-name></person-group>. <article-title>Patterns of use and harms associated with non- medical ketamine use</article-title>. <source>Drug Alcohol Depend</source> <volume>69</volume>, <fpage>23</fpage>–<lpage>28</lpage> (<year>2003</year>).</mixed-citation></ref>
<ref id="c74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morgan</surname>, <given-names>C. J. A.</given-names></string-name> &amp; <string-name><surname>Curran</surname>, <given-names>H. V</given-names></string-name></person-group>. <article-title>Ketamine use: A review</article-title>. <source>Addiction</source> <volume>107</volume>, <fpage>27</fpage>–<lpage>38</lpage> (<year>2012</year>).</mixed-citation></ref>
<ref id="c75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ryder</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Way</surname>, <given-names>W. L.</given-names></string-name> &amp; <string-name><surname>Trevor</surname>, <given-names>A. J</given-names></string-name></person-group>. <article-title>Comparative pharmacology of the optical isomers of ketamine in mice</article-title>. <source>Eur J Pharmacol</source> <volume>49</volume>, <fpage>15</fpage>–<lpage>23</lpage> (<year>1978</year>).</mixed-citation></ref>
<ref id="c76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Finck</surname>, <given-names>A. D.</given-names></string-name> &amp; <string-name><surname>Ngai</surname>, <given-names>S. H</given-names></string-name></person-group>. <article-title>Opiate receptor mediation of ketamine analgesia</article-title>. <source>Anesth Analg</source> <volume>56</volume>, <fpage>291</fpage>–<lpage>297</lpage> (<year>1982</year>).</mixed-citation></ref>
<ref id="c77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hustveit</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Maurset</surname>, <given-names>A.</given-names></string-name> &amp; <string-name><surname>Oye</surname>, <given-names>I</given-names></string-name></person-group>. <article-title>Interaction of the Chiral Forms of Ketamine with Opioid, Phencyclidine, c and Muscarinic Receptors</article-title>. <source>Pharmacol Toxicol</source> <volume>77</volume>, <fpage>355</fpage>–<lpage>359</lpage> (<year>1995</year>).</mixed-citation></ref>
<ref id="c78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bonaventura</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Pharmacological and behavioral divergence of ketamine enantiomers:implications for abuse liability</article-title>. <source>Mol Psychiatry</source> <volume>26</volume>, <fpage>6704</fpage>–<lpage>6722</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Williams</surname>, <given-names>N. R.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism</article-title>. <source>Mol Psychiatry</source> <volume>24</volume>, <fpage>1779</fpage>–<lpage>1786</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Williams</surname>, <given-names>N. R.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Attenuation of antidepressant effects of ketamine by opioid receptor antagonism</article-title>. <source>American Journal of Psychiatry</source> <volume>175</volume>, <fpage>1205</fpage>–<lpage>1215</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gelernter</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Genome-wide association study of opioid dependence: Multiple associations mapped to calcium and potassium pathways</article-title>. <source>Biol Psychiatry</source> <volume>76</volume>, <fpage>66</fpage>–<lpage>74</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Malcolm</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Brady</surname>, <given-names>K. T.</given-names></string-name>, <string-name><surname>Moore</surname>, <given-names>J.</given-names></string-name> &amp; <string-name><surname>Kajdasz</surname>, <given-names>D</given-names></string-name></person-group>. <article-title>Amlodipine treatment of cocaine dependence</article-title>. <source>J Psychoactive Drugs</source> <volume>31</volume>, <fpage>117</fpage>–<lpage>120</lpage> (<year>1999</year>).</mixed-citation></ref>
<ref id="c83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Altamura</surname>, <given-names>A. C.</given-names></string-name>, <string-name><surname>Regazzetti</surname>, <given-names>M. G.</given-names></string-name> &amp; <string-name><surname>Porta</surname>, <given-names>M</given-names></string-name></person-group>. <article-title>Nimodipine in human alcohol withdrawal syndrome - an open study</article-title>. <source>European Neuropsychopharmacology</source> <volume>1</volume>, <fpage>37</fpage>–<lpage>40</lpage> (<year>1990</year>).</mixed-citation></ref>
<ref id="c84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rosse</surname>, <given-names>R.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Nimodipine Pharmacotherapeutic Adjuvant Therapy for Inpatient Treatment of Cocaine Dependence</article-title>. <source>Clin Neuropharmacol</source> <volume>17</volume>, <fpage>348</fpage>–<lpage>358</lpage> (<year>1994</year>).</mixed-citation></ref>
<ref id="c85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Muntaner</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Kumor</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Nagoshi</surname>, <given-names>C.</given-names></string-name> &amp; <string-name><surname>Jaffe</surname>, <given-names>J</given-names></string-name></person-group>. <article-title>Effect of nifedipine pretreatment on subjective and cardiovascular responses to intravenous cocaine in humans</article-title>. <source>Drug Alcohol Depend</source> <volume>105</volume>, <fpage>37</fpage>–<lpage>41</lpage> (<year>1991</year>).</mixed-citation></ref>
<ref id="c86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johnson</surname>, <given-names>B. A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Effects of Isradipine on Cocaine-Induced Subjective Mood</article-title>. <source>J Clin Psychopharmacol</source> <volume>24</volume>, <fpage>180</fpage>–<lpage>191</lpage> (<year>2004</year>).</mixed-citation></ref>
<ref id="c87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vaupel</surname>, <given-names>D. B.</given-names></string-name>, <string-name><surname>Lange</surname>, <given-names>W. R.</given-names></string-name> &amp; <string-name><surname>London</surname>, <given-names>E. D</given-names></string-name></person-group>. <article-title>Effects of verapamil on morphine-induced euphoria, analgesia and respiratory depression in humans</article-title>. <source>Journal of Pharmacology and Experimental Therapeutics</source> <volume>267</volume>, <fpage>1386</fpage>–<lpage>1394</lpage> (<year>1993</year>).</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.93664.2.sa4</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Uchida</surname>
<given-names>Naoshige</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5755-9409</contrib-id>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Harvard University</institution>
</institution-wrap>
<city>Cambridge</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Convincing</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Important</kwd>
</kwd-group>
</front-stub>
<body>
    <p>This <bold>important</bold> study by Bartas and colleagues examined how patterns of monosynaptic input to specific cell types in the ventral tegmental area are altered by drugs of abuse. The authors applied a dimensionality reduction approach (principal component analysis) and showed that various drugs of abuse, and somewhat surprisingly the anesthesia alone (ketamine/xylasin), caused changes in the distribution of inputs labeled by the transsynaptic rabies virus. The evidence supporting the conclusions is overall <bold>convincing</bold> and provides foundational information, as well as a cautionary note on the interpretation of rabies virus-based tracing experiments.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.93664.2.sa3</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>In this study, the authors mapped afferent inputs to distinct cell populations in the ventral tegmental area (VTA) using dimensionality reduction techniques, revealing markedly different connectivity patterns under normal versus drug-treated conditions. They further showed that drug-induced changes in inputs were negatively correlated with the expression of ion channels and proteins involved in synaptic transmission. Functional validation demonstrated that knockdown of a specific voltage-gated calcium channel led to reduced afferent inputs, highlighting a causal link between gene expression and connectivity.</p>
<p>The authors have clearly addressed the reviewers' previous comments. The study's earlier weaknesses were thoroughly discussed, and additional data were provided to strengthen the findings. Overall, the revised version incorporates more extensive datasets and analyses, resulting in a more robust and compelling study.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.93664.2.sa2</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>The application of rabies virus (RabV)-mediated transsynaptic tracing has been widely utilized for mapping cell-type-specific neural connectivities and examining potential modifications in response to biological phenomena or pharmacological interventions. Despite the predominant focus of studies on quantifying and analyzing labeling patterns within individual brain regions based on labeling abundance, such an approach may inadvertently overlook systemic alterations. There exists a considerable opportunity to integrate RabV tracing data with the global connectivity patterns and the transcriptomic signatures of labeled brain regions. In the present study, the authors take an important step towards achieving these objectives.</p>
<p>Specifically, the authors conducted an intensive reanalysis of a previously generated large dataset of RabV tracing to the ventral tegmental area (VTA) using dimension reduction methods such as PCA and UMPA. This reaffirmed the authors's earlier conclusion that different cell types in the VTA, namely dopamine neurons (DA) and GABAergic neurons, exhibit quantitatively distinct input patterns, and a single dose of addictive drugs, such as cocaine and morphine, induced altered labeling patterns. Additionally, the authors illustrate that distinct axes of PCA can discriminate experimental variations, such as minor differences in the injection site of viral tracers, from bona fide alterations in labeling patterns caused by drugs of abuse. While the specific mechanisms underlying altered labeling in most brain regions remain unclear, whether involving synaptic strength, synaptic numbers, pre-synaptic activities, or other factors, the present study underscores the efficacy of an informatics approach in extracting more comprehensive information from the RabV-based circuit mapping data.</p>
<p>Moreover, the authors showcased the utility of their previously devised bulk gene expression patterns inferred by the Allen Gene Expression Atlas (AGEA) and &quot;projection portrait&quot; derived from bulk axon mapping data sourced from the Allen Mouse Brain Connectivity Atlas. The utilization of such bulk data rests upon several limitations. For instance, the collection of axon mapping data involves an arbitrary selection of both cell type-specific and non-specific data, which might overlook crucial presynaptic partners, and often includes contamination from neighboring undesired brain regions. Concerns arise regarding the quantitativeness of AGEA, which may also include the potential oversight of key presynaptic partners. Nevertheless, the authors conscientiously acknowledged these potential limitations associated with the dataset.</p>
<p>Notably, building on the observation of a positive correlation between the basal expression levels of Ca2+ channels and the extent of drug-induced changes in RabV labeling patterns, the authors conducted a CRISPRi-based knockdown of a single Ca2+ channel gene. This intervention resulted in a reduction of RabV labeling, supporting that the observed gene expression patterns have causality in RabV labeling efficiency. While a more nuanced discussion is necessary for interpreting this result (see below), overall I commend the authors for their efforts to leverage the existing dataset in a more meaningful way. This endeavor has the potential to contribute significantly to our understanding of the mechanisms underlying alterations in RabV labeling induced by drugs of abuse.</p>
<p>Finally, drawing upon the aforementioned reanalysis of previous data, the authors underscored that a single administration of ketamine/xylazine anesthesia could induce enduring modifications in RabV labeling patterns for VTA DA neurons, specifically those projecting to the nucleus accumbens and amygdala. Given the potential impact of such alterations on motivational behaviors at a broader level, I fully agree that prudent consideration is warranted when employing ketamine/xylazine for the investigation of motivational behaviors in mice.</p>
<p>Comments on revisions:</p>
<p>In the re-revised version, the authors have addressed all of my previous comments. I no longer have any major concerns.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.93664.2.sa1</article-id>
<title-group>
<article-title>Reviewer #3 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>Authors mapped monosynaptic inputs to dopamine, GABA, and glutamate neurons in the ventral tegmental area (VTA) under different anesthesia methods, and under drug (cocaine, morphine, methamphetamine, amphetamine, nicotine, fluoxetine). First, they propose an analysis method to separate the actual manipulation effects from the variability caused by experimental procedures. Using this method, they found differences in the anatomical location of monosynaptic inputs to dopamine neurons under different conditions, and identified some key brain areas for such separation. They also searched the database for gene expression patterns that are common across input brain areas, with some changes by anesthesia or drug administration.</p>
<p>Strengths:</p>
<p>The whole-brain approach to address drug effects is appealing, and their conclusion is clear. The methodology and motivation are clearly explained.</p>
<p>Weaknesses:</p>
<p>While gene expression analyses may not be related to their findings on the anatomical effects of drugs, this is a nice starting point for follow-up studies.</p>
</body>
</sub-article>
<sub-article id="sa4" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.93664.2.sa0</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bartas</surname>
<given-names>Katrina</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Derdeyn</surname>
<given-names>Pieter</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tian</surname>
<given-names>Guilian</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vasquez</surname>
<given-names>Jose J</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Azouz</surname>
<given-names>Ghalia</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yamamoto</surname>
<given-names>Cindy M</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hui</surname>
<given-names>May</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Beier</surname>
<given-names>Kevin T</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4934-1338</contrib-id></contrib>
</contrib-group>
</front-stub>
<body>
<p>The following is the authors’ response to the original reviews.</p>
<disp-quote content-type="editor-comment">
<p><bold>Public Reviews:</bold></p>
<p><bold>Reviewer #1(Public review):</bold></p>
<p>Summary:</p>
<p>In this study, the authors distinguished afferent inputs to different cell populations in the VTA using dimensionality reduction approaches and found significantly distinct patterns between normal and drug treatment conditions. They also demonstrated negative correlations of the inputs induced by drugs with gene expression of ion channels or proteins involved in synaptic transmission and demonstrated the knockdown of one of the voltage-gated calcium ion channels caused decreased inputs.</p>
<p>Weaknesses:</p>
<p>(1) For quantifications of brain regions in this study, boundaries were based on the Franklin-Paxinos (FP) atlas according to previous studies (Beier KT et al 2015, Beier KT et al 2019). It has been reported significant discrepancies exist between the anatomical labels on the FP atlas and the Allen Brain Atlas (ref: Chon U et al., Nat Commun 2019). Although a summary of conversion is provided as a sheet, the authors need to describe how consistent or different the brain boundaries they defined in the manuscript with Allen Brain Atlas by adding histology images. Also, I wonder how reliable the annotations were for over a hundred of animals with manual quantification. The authors should briefly explain it rather than citing previous studies in the Material and Methods Section.</p>
</disp-quote>
<p>We thank the reviewer for attention to this point; indeed, neuroanatomical detail is often overlooked in modern neuroscience, occasionally leading to spurious conclusions. We acknowledge that there are significant discrepancies in brain region definitions across atlases, which can make cross-study comparisons difficult. Here, all cells were manually quantified by Dr. Kevin Beier, as in previous studies (Beier et al., Cell 2015; Nature 2017; Cell Reports 2019; Tian et al., Cell Reports 2022; Tian et al., Neuron 2024; Hubbard et al., Neuropsychopharmacology, 2025). As such, these studies are internally consistent as relates to the definition of brain regions, which is critical here since our analysis in this manuscript relates to data quantified only by a single individual. Several brain regions were quite easy to distinguish anatomically, such as the medial habenula and lateral habenula. Others, such as the extended amygdala area, are much more difficult. We have now provided example images in Figure S1 that detail the anatomical boundaries that we used, overlayed on images of Neurotrace blue (fluorescent Nissl stain).</p>
<disp-quote content-type="editor-comment">
<p>(2) Regarding the ellipsoids in the PC, although it's written in the manuscript that &quot;Ellipsoids were centered at the average coordinate of a condition and stretched one standard deviation along the primary and secondary axes&quot;, it's intuitively hard to understand in some figures such as Figure 2O, P and Figure S1. The authors need to make their data analysis methods more accessible by providing source code to the public.</p>
</disp-quote>
<p>The source code is now available to the public at <ext-link ext-link-type="uri" xlink:href="https://github.com/ktbartas/Bartas_et_al_eLife_2024">https://github.com/ktbartas/Bartas_et_al_eLife_2024</ext-link>, which is noted in the Code Availability statement. The code for generating ellipsoids is in the first notebook, `0-dataexploration-master-euclidean.ipynb`, in the function `confidence_ellipse`, which is called from `make_pca_plots` and `umap_and_heatmap`. Example plots are all live in the notebooks as can be viewed directly from GitHub.</p>
<disp-quote content-type="editor-comment">
<p>(3) In histology images (Figure 1B and 3K), the authors need to add dashed lines or arrows to guide the reader's attention.</p>
</disp-quote>
<p>Dashed lines have been added to these figure panels as requested.</p>
<disp-quote content-type="editor-comment">
<p>(4) In Figure 2A and G, apparently there are significant differences in other brain regions such as NAcMed or PBN. If they are also statistically significant, the authors should note them as well and draw asterisks(*).</p>
</disp-quote>
<p>We appreciate the care in ensuring that statistics are being applied and shown appropriately. In panel A (now Figure 3A), the Two-way ANOVA interaction term was not significant (p = 0.9365), we did not find it justified to do further comparisons. However, for Figure 3G, the interaction term was significant (p = 0.0001), and thus further pairwise comparisons were performed with Sidak's correction for multiple comparisons. When done, the only two brain regions that were significantly different were the DStr (p = 0.0051) and GPe (p = 0.0036). While the NAcMed and PBN visually look different, according to the corrected statistics, they were not significantly different (NAcMed p = 0.5037, PBN p = 0.8123). The notations in our original figure thus accurately reflected these statistics.</p>
<disp-quote content-type="editor-comment">
<p>(5) In Figure 2N about the spatial distribution of starter cells, the authors need to add histology images for each experimental condition (i.e. saline, fluoxetine, cocaine, methamphetamine, amphetamine, nicotine, and morphine) as supplement figures</p>
</disp-quote>
<p>We have now provided these as Figure S2.</p>
<disp-quote content-type="editor-comment">
<p>(6) In the manuscript, it is necessary to explain why Cacna1e was selected among other calcium ion channels.</p>
</disp-quote>
<p>We have added a sentence to the &quot;Functional validation of link between gene expression and RABV labeling&quot; section (lines 722-724).</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Public review):</bold></p>
<p>The application of rabies virus (RabV)-mediated transsynaptic tracing has been widely utilized for mapping celltype-specific neural connectivities and examining potential modifications in response to biological phenomena or pharmacological interventions. Despite the predominant focus of studies on quantifying and analyzing labeling patterns within individual brain regions based on labeling abundance, such an approach may inadvertently overlook systemic alterations. There exists a considerable opportunity to integrate RabV tracing data with the global connectivity patterns and the transcriptomic signatures of labeled brain regions. In the present study, the authors take an important step towards achieving these objectives. Specifically, the authors conducted an intensive reanalysis of a previously generated large dataset of RabV tracing to the ventral tegmental area (VTA) using dimension reduction methods such as PCA and UMPA. This reaffirmed the authors' earlier conclusion that different cell types in the VTA, namely dopamine neurons (DA) and GABAergic neurons, exhibit quantitatively distinct input patterns, and a single dose of addictive drugs, such as cocaine and morphine, induced altered labeling patterns. Additionally, the authors illustrate that distinct axes of PCA can discriminate experimental variations, such as minor differences in the injection site of viral tracers, from bona fide alternations in labeling patterns caused by drugs of abuse. While the specific mechanisms underlying altered labeling in most brain regions remain unclear, whether involving synaptic strength, synaptic numbers, pre-synaptic activities, or other factors, the present study underscores the efficacy of an informatics approach in extracting more comprehensive information from the RabV-based circuit mapping data. Moreover, the authors showcased the utility of their previously devised bulk gene expression patterns inferred by the Allen Gene Expression Atlas (AGEA) and &quot;projection portrait&quot; derived from bulk axon mapping data sourced from the Allen Mouse Brain Connectivity Atlas. The utilization of such bulk data rests upon several limitations. For instance, the collection of axon mapping data involves an arbitrary selection of both cell type-specific and non-specific data, which might overlook crucial presynaptic partners, and often includes contamination from neighboring undesired brain regions. Concerns arise regarding the quantitativeness of AGEA, which may also include the potential oversight of key presynaptic partners. Nevertheless, the authors conscientiously acknowledged these potential limitations associated with the dataset. Notably, building on the observation of a positive correlation between the basal expression levels of Ca2+ channels and the extent of drug-induced changes in RabV labeling patterns, the authors conducted a CRISPRi-based knockdown of a single Ca2+ channel gene. This intervention resulted in a reduction of RabV labeling, supporting that the observed gene expression patterns have causality in RabV labeling efficiency. While a more nuanced discussion is necessary for interpreting this result (see below), overall I commend the authors for their efforts to leverage the existing dataset in a more meaningful way. This endeavor has the potential to contribute significantly to our understanding of the mechanisms underlying alterations in RabV labeling induced by drugs of abuse. Finally, drawing upon the aforementioned reanalysis of previous data, the authors underscored that a single administration of ketamine/xylazine anesthesia could induce enduring modifications in RabV labeling patterns for VTA DA neurons, specifically those projecting to the nucleus accumbens and amygdala. Given the potential impact of such alterations on motivational behaviors at a broader level, I fully agree that prudent consideration is warranted when employing ketamine/xylazine for the investigation of motivational behaviors in mice.</p>
<p>Specific Points:</p>
<p>(1) Beyond advancements in bioinformatics, readers may find it insightful to explore whether the PCA/UMPAbased approach yields novel biological insights. For example, the authors are encouraged to discuss more functional implications of PBN and LH in the context of drugs of abuse, as their labeling abundance could elucidate the PC2 axis in Fig. 2M.</p>
</disp-quote>
<p>Thank you for this suggestion: we added text (Lines 787-795) discussing the LH and PBN (and GPe) specifically, but also highlighted the importance of our approach in hypothesis-generating science.</p>
<disp-quote content-type="editor-comment">
<p>(2) While I appreciate the experimental data on Cacna1e knockdown, I am unclear about the rationale behind specifically focusing on Cacna1e. The logic behind the statement, &quot;This means that expression of this gene is not inhibitory towards RABV transmission,&quot; is also unclear. Loss-of-function experiments only signify the necessity or permissive functions of a gene. In this context, Cacna1e expression levels are required for efficient RabV labeling, but this neither supports nor excludes the possibility that this gene expression instructively suppresses RabV labeling/transmission, which could be assessed through gain-of-function experiments.</p>
</disp-quote>
<p>We thank the reviewer for their suggestions regarding this result, and agree that a gain-of-function would be required to provide clearer evidence on this point.  We therefore understand that our original phrasing may be misleading. Thus, we have edited this section to the more conservative statement: “These results indicate that reduced levels of Cacna1e likely lower the number of RABV-labeled inputs from the NAcLat, and directly link the levels of Cacna1e and RABV input labeling” (lines 742-744) - we refrain from over-interpreting the results. As mentioned above in response to R1, we added a sentence to explain the rationale behind focusing on Cacna1e (lines 722-724).</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #3 (Public Review):</bold></p>
<p>Summary:</p>
<p>Authors mapped monosynaptic inputs to dopamine, GABA, and glutamate neurons in VTA under different anesthesia methods, and under drugs (cocaine, morphine, methamphetamine, amphetamine, nicotine, fluoxetine). They found that input patterns under different conditions are separated, and identified some key brain areas to contribute to such separation. They also searched a database for gene expression patterns that are common across input brain areas with some changes by anesthesia or drug administration.</p>
<p>Strengths:</p>
<p>The whole-brain approach to address drug effects is appealing and their conclusion is clear. The methodology and motivation are clearly explained.</p>
<p>Weaknesses:</p>
<p>While gene expression analyses may not be related to their findings on the anatomical effects of drugs, this will be a nice starting point for follow-up studies.</p>
</disp-quote>
<p>We understand and agree with the suggestion that gene expression allows us to provide correlative observations between in situ hybridization datasets and rabies mapping datasets, and that these results do not show causality. As such, future studies would be needed to assess this in more detail. We have added a line in the discussion to this effect (lines 851-853).</p>
<disp-quote content-type="editor-comment">
<p><bold>Recommendations for the authors:</bold></p>
<p><bold>Reviewer #1 (Recommendations for the authors):</bold></p>
<p>Recommendations for improving the writing and presentation:</p>
<p>(1) There are a couple of packages available for 3D whole-brain reconstructions based on Allen Brain Atlas (eg. <ext-link ext-link-type="uri" xlink:href="https://github.com/tractatus/wholebrain">https://github.com/tractatus/wholebrain</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://github.com/lahammond/BrainJ">https://github.com/lahammond/BrainJ</ext-link>), which would be helpful to align with the gene expression or other data from Allen Institute.</p>
</disp-quote>
<p>This comment is related to the noted weakness we responded to previously in this rebuttal also from R1 (see comment 1), about the discrepancies between the Franklin-Paxinos atlas and Allen Brain atlas. We agree that a systematic comparison of these two atlases using a tool like wholebrain or BrainJ would be valuable for the field. However, it would be a substantial amount of work, and likely would be an independent study in itself. We believe that the resolution of these atlases was sufficient to make our key conclusions here (e.g., identify gene expression patterns that relate to drug-induced changes rabies virus labeling patterns, and develop a testable hypothesis for CRISPR-based gene editing). They are also based on the same atlases and region definitions that have been applied in our previous studies (e.g., Beier et al., Cell 2015; Beier et al., Nature 2017; Beier et al., Cell Reports 2019; Tian et al., Cell Reports 2022; Tian et al., Neuron 2024; Hubbard et al., Neuropsychophamacology 2025, etc.)  The expression of Cacna1e is relatively consistent across the NAc, as we have now detailed in Figure S13.</p>
<disp-quote content-type="editor-comment">
<p>(2) There are so far two kinds of rabies virus strains available in the neuroscience field (SAD-B19 or CVS-N2c). It is recommended to describe which strain was used in the Material and Methods Section because labeling efficiency and toxicity is quite different between the strains (Reardon TR et al., Neuron 2016).</p>
</disp-quote>
<p>We have now noted that we used SAD B19 for all experiments (Lines 141-142).</p>
<disp-quote content-type="editor-comment">
<p>Minor corrections to the text and figures:</p>
<p>(1)  In Figure 1A, the color differences are not clear (i.e. light gray and dark gray). The figure can be simplified.</p>
<p>In addition, generally, images/figures are recommended not to be overlapped with other figures/images (Figures 2A-F, 2G-L).</p>
<p>(2)  In Figures 7C and D, the authors could add enlarged views of starter cells in VTA and NAcLat.</p>
</disp-quote>
<p>We have attempted to simplify schematics and figures throughout. High-magnification images of cells have been added as insets in what is now Figure 10 (formerly Figure 7).</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Recommendations For the authors):</bold></p>
<p>The number of animals for each graph should be explicated within the figure legend. For example, Figure 1C and Figure 7E lack this information. It is also advisable to delineate the definition of error bars within the figure legend.</p>
</disp-quote>
<p>We have now added mouse numbers to all figures and/or legends, as appropriate. We also indicated in the legend at the end of Figure 1 how error bars and asterisks are defined. Furthermore, we added a sentence to the methods saying that in UMAP and PCA plots each dot is an animal (lines 244-245).</p>
<disp-quote content-type="editor-comment">
<p>The visual representations, particularly in Figures 1 and 3, are overcrowding. Furthermore, the arrangement of figure subpanels does not consistently adhere to the sequence of explication in the main text, significantly compromising the readability of the text. The authors are encouraged to consider the possibility of segmenting dense figures into two if there exists no upper limit for the number of figure displays. To illustrate, in Figure 3Q, crucial details about experimental conditions are denoted by numerical references, owing to spatial constraints.</p>
</disp-quote>
<p>We agree that the figure layout and mis-alignment with a linear read of the text was unideal. Therefore, we broke our figures, especially the original Figures 1-4, into multiple sub-figures, including both main and supplemental figures. This facilitated the use of space to rearrange the figure panels, allowing the story to be told in a linear fashion. All figures and panels should now be read in order.</p>
<disp-quote content-type="editor-comment">
<p>I am seeking clarification on how to interpret the term &quot;overlap&quot; at the bottom of figures illustrating Gene Ontology analysis.</p>
</disp-quote>
<p>We have clarified the meaning of overlap in this context (lines 324-325): The ‘overlap’ term on the x-axis of these plots means the number of genes in the correlated gene lists that were also within the list of genes for the corresponding GO term.</p>
<disp-quote content-type="editor-comment">
<p>The authors could provide Cacna1e gene expression patterns within the NAc from the AGEA data.</p>
</disp-quote>
<p>Cacna1e expression data are now provided in Figure S13.</p>
<disp-quote content-type="editor-comment">
<p>Additionally, the meaning of &quot;controls&quot; in Figure 7F, along with the &quot;No gRNA&quot; condition, remains ambiguous. While the text mentions &quot;no shRNA&quot;, the involvement of shRNA in this experiment lacks clarity.</p>
</disp-quote>
<p>We now clarify that the control conditions are based on previously published data where no AAVs were injected into NAcLat. This is now clarified in the legend for Figure 10F (lines 1277-1578). We also corrected “shRNA” to “gRNA” in the text.</p>
</body>
</sub-article>
</article>